MTOR SIGNALING PATHWAY ASSOCIATED WITH SKELETAL MUSCLE HYPERTROPHY FOLLOWING RESISTANCE EXERCISE TRAINING by Newman, Mark A
 MTOR SIGNALING PATHWAY ASSOCIATED WITH SKELETAL MUSCLE 
HYPERTROPHY FOLLOWING RESISTANCE EXERCISE TRAINING. 
 
 
 
 
 
 
 
 
 
by 
Mark A. Newman 
BS, Indiana University of Pennsylvania, 1998 
MS, Indiana University of Pennsylvania, 2000 
 
MPH, University of Pittsburgh, 2007 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
the School of Education in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
University of Pittsburgh 
 
 
2008 
Steven E. Riechman, PhD, Assistant Professor 
Bret H. Goodpaster, PhD, Associate Professor 
Robert J. Robertson, PhD, Professor 
 Dissertation Advisor: Frederic L. Goss, PhD, Associate Professor 
 
 
UNIVERSITY OF PITTSBURGH 
SCHOOL OF EDUCATION 
 
 
 
 
 
 
 
 
This dissertation was presented 
 
by 
 
 
Mark A. Newman 
 
 
 
It was defended on 
[Month date, year]anaaand approved by 
 
 
It was defended on 
July 14, 2008 
and approved by
 ii 
MTOR SIGNALING PATHWAY ASSOCIATED WITH SKELETAL MUSCLE 
HYPERTROPHY FOLLOWING RESISTANCE EXERCISE TRAINING. 
 
Mark A. Newman, PhD 
University of Pittsburgh, 2008
 
Objective:  The purpose of this investigation is to examine the association of genetic variations 
in 4 single nucleotide polymorphisms (SNPs) of the AKT1 gene and 3 SNPs of the AMPKα2 
gene with percent change in lean muscle mass, arm mass-adjusted strength, and leg mass-
adjusted strength following a resistance exercise training (RET) program while controlling for 
the effects of age, gender, and RET history.  These genes are part of the mTOR signaling 
pathway, which has been shown to be an important mediator of protein synthesis in adult 
animals.  Design:  Participants were young men and women (age 18-31) from the Molecular 
Epidemiology of Resistance Exercise Training (MERET) study who completed 10 weeks of 
RET.  Participants trained 3 days per week at 75% of one repetition maximum, performing 3 sets 
(6-10 repetitions) of 13 resistance exercises.  Results: There were no significant associations 
between the individual AKT1 and AMPKα2 SNPs examined in this investigation to percent 
changes in lean muscle mass, arm mass-adjusted strength, or leg mass-adjusted strength 
following RET.  However, significant interactions between various SNPS of the AKT1 and 
AMPKα2 genes and measures of muscle mass and strength were observed.  Conclusion: The 
results of this investigation suggest that future research involving the mTOR signaling pathway 
and its association to variations in the individual response of skeletal muscle response to 
standardized RET is warranted.        
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1.0  INTRODUCTION 
Skeletal muscle is the most abundant tissue in the human body, and maintenance of its mass is 
essential for such basic functions as ambulation, metabolism, and respiration.  Resistance 
exercise, involving either free weights or specifically designed machines, is the most common 
way to maintain or increase muscle mass.  Resistance exercise causes an increase in the 
recruitment rate of motor units and a marked increase in the load against which the recruited 
motor units contract (1).    The human body adapts to resistance exercise training (RET) by 
increasing the cross-sectional area of the muscle, this is called hypertrophy (1).  The fibers of 
untrained muscle vary considerably in diameter.  In adult human beings, the cross-sectional area 
of an individual muscle fiber ranges from approximately 2000µm2 to 7500µm2 with the mean 
and median in the 3000-4000µm2 range (1).  RET brings the smaller muscle fibers up to the size 
of the larger ones (2).  Fast-twitch muscle fibers (type II), which are known to supply quick 
bursts of power but fatigue quickly, typically hypertrophy to a greater extent than slow twitch 
fibers (type I), which are more suited for endurance activities and fatigue at a much slower rate 
(3).  In a longitudinal study that compared the cross-sectional area of the triceps brachii muscle 
before and after six months of resistance training, the type II fibers hypertrophied by 33% and 
the type I fibers by 27%(4).  The nervous system also plays a role in the human body’s 
adaptation to RET.  The nervous system adapts to RET by increasing the number of motor units 
being activated, producing an improved recruitment pattern and synchronization of these motor 
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units, thus more power can be generated due to the increased number of muscle fibers involved  
(2). 
1.1 RET AND PROTEIN SYNTHESIS 
Protein synthesis is the process in which cells build protein.  Protein synthesis is a multi-step 
process which begins with amino acid synthesis, followed by transcription and subsequently 
translation.  Amino acid synthesis is a set of biochemical processes which build the amino acids 
from carbon sources like glucose (5). Transcription is the process in which deoxyribonucleic acid 
(DNA) is transferred into ribonucleic acid (RNA).  RNA then serves as the template for the 
translation of genes into proteins, transferring the amino acids to the ribosome of the cell where 
they are assembled into proteins (5). 
The primary acute response to resistance exercise is an increase in the rate of protein 
synthesis.  The protein content of skeletal muscle is in a constant state of change. The rates of 
protein synthesis and degradation change based on the demands placed on the body.  Muscular 
hypertrophy results from an accumulation of proteins, this can happen because of an increased 
rate of production, a decreased rate of degradation, or a combination of the two (4).  During 
resistance exercise, protein synthesis decreases while protein degradation increases.  However, 
protein synthesis has been shown to increase during the recovery phase of resistance exercise (6).  
Protein synthesis in response to RET is stimulated by the combination of insulin, along with an 
increase in amino acid availability.  This process in turn stimulates the translation of messenger 
RNA, leading to protein synthesis (7).  Regulation of these translation initiation steps is 
controlled through the phosphorylation of initiation factors and protein kinases that are 
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controlled by signaling pathways downstream of the phosphatidylinositol 3-kinase (PI3K), which 
is a gene that is part of the mTOR signaling pathway (6).  
1.2 MTOR SIGNALING PATHWAY AND PROTEIN SYNTHESIS 
Modifications in the magnitude, frequency, duration, and intensity of mechanical stress can each 
cause changes in patterns of gene expression in muscle, influence protein synthesis and stability, 
and affect muscle metabolism to produce adaptations in muscle mass (8).  These adaptations are 
accomplished through signal transduction by which an extra cellular signal interacts with 
receptors at the cell surface, activating signaling pathways which act on myofibers by changing 
gene expression (9).  Genes that are part of a particular signaling pathway interact with each 
other in various ways before a biological outcome is produced.  RET is well known to result in 
marked increases in muscle mass and strength but the responses to a standardized program vary 
considerably among individuals (10).  The reasons for this inter-individual variability are largely 
unknown.  However, the answer may lie in part, among variability in signaling pathways that 
control protein synthesis.  
 The mammalian target of rapamycin (mTOR) signaling pathway (Figure 1) has been 
shown to be an important mediator of protein synthesis and subsequently muscle fiber size in 
adult animals (11).  However, molecular signaling pathways are rarely linear and often have 
many branch points and multiple places at which signaling events can activate the cascade of 
reactions.  Genes that are part of a signaling pathway stimulate other genes that lie downstream 
in the pathway by either activating or inhibiting their effects.  Under normal conditions, this 
cascade of reactions produces the biological outcome of the signaling pathway, in the case of the 
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mTOR signaling pathway this outcome is protein translation and cell growth. However, if any of 
the genes in the signaling pathway are not functioning properly, the process of signal 
transduction could be compromised.  Genetic variations in the mTOR signaling pathway may 
cause one individual to respond more favorably to a RET program than another person, 
environmental conditions being equal.     
 
 
Figure 1 mTOR Signaling Pathway.  Genes connected by ---> represent activating steps and genes       
connected by ---| represent inhibitory steps.  Source: National Center for Biotechnology Information. 
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1.3 SIGNIFICANCE 
It is of interest to study the cellular mechanisms behind muscle hypertrophy to understand how 
muscle mass may be maintained or increased but also to find ways to combat muscle atrophy.  
Muscle may begin to atrophy as a result of muscle wasting diseases like cancer and AIDS, 
immobilization due to an orthopedic injury, or the normal aging process. Gaining a better 
understanding of the signaling pathways involved with muscle hypertrophy will not only 
increase the knowledge of basic muscle biology but may be the essential step in the discovery of 
anti-atrophy drugs.  Currently, there are no safe, effective, and approved drugs to treat muscle 
atrophy.  The relatively new technique of studying a gene pathway, as opposed to a single gene, 
will allow for the examination of how particular genetic variations in the mTOR signaling 
pathway interact to effect muscle mass increases with resistance exercise training. 
Genes that are part of the mTOR signaling pathway interact in a cascade of reactions to 
produce cell growth.  Some of the genes in this pathway act on each other by regulating activity.  
These genes act like a light switch, turning each other on and off as the cascade of reactions goes 
from beginning to end.  Studying several genes in the pathway that are known from previous 
investigations to interact will allow a more comprehensive view of the process.   Variations in 
these genes could compromise protein synthesis and cell growth, the biological outcomes of the 
mTOR signaling pathway.  These variations could also be the target of interventions designed to 
treat disease and aging associated muscle atrophy.  
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1.4 STATEMENT OF THE PROBLEM 
The primary purpose of this investigation was to examine the association of genetic variations in 
selected genes of the mTOR signaling pathway with percent change in lean muscle mass 
following a RET program while also controlling for any covariance due to gender, age (<19.5 
years or >19.5 years) and RET history (0 hours per week, 0.1-1.8 hours per week or >1.8 hours 
per week during the past year).  A secondary analysis examined the association of genetic 
variations in selected genes of the mTOR signaling pathway with percent changes in arm and leg 
mass-adjusted strength following an RET program while also controlling for the effects of 
gender, age, and RET history. 
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2.0  CONCEPTUAL FRAMEWORK 
2.1 GENETIC VARIATION 
A single nucleotide polymorphism (SNP) is a DNA sequence variation that occurs when a single 
nucleotide: adenine (A), thymine (T), cytosine (C), or guanine (G) in the genome differs between 
individuals.  For example, two DNA fragments from different individuals AAGCCTA to 
AAGCTTA, contain a difference in a single nucleotide.  This combination produces two alleles 
C and T, almost all common SNPs have two common alleles.  An allele is one of any number of 
viable DNA combinations occupying a locus (position) on a chromosome.  An individuals 
genotype for that gene is the set of alleles it happens to possess (12). 
Humans are diploid organisms; that is they have paired homologous chromosomes in 
their cells, and these contain two copies of each gene.  Organisms in which two copies of the 
gene have the same alleles are homozygous for that gene.  In contrast, an organism which has 
two different alleles for that gene is called heterozygous.  Phenotypes are the expressed 
characteristics associated with a certain allele and can be dominant, recessive, or neither.  A 
dominant phenotype will be expressed when at least one allele of its associated phenotype is 
present, whereas a recessive phenotype will only be expressed when both alleles are of its 
associated type (12).  
 
 7 
 Genetic variations can come in the form of mutations which produce amino acid 
sequence changes (nonsynonomous), in genes, and those that may not (synonomous).  
Synonymous mutations change the nucleotide base triplet (codon) produced but do not alter the 
amino acid encoded.  These mutations are usually neutral if they occur in a noncoding region of 
DNA.  However, if they occur in a coding region of DNA they could influence gene expression 
by altering a DNA sequence that regulates how a particular gene is expressed. Nonsynonymous 
variations can result in the occurrence of a missense mutation or a nonsense mutation. A 
missense mutation occurs when a nucleotide substitution results in an incorrect amino acid 
change. These effects can be minimal if the amino acid substituted is chemically similar to the 
one specified (12). 
If the amino acids are chemically dissimilar, gene function could be compromised.  A 
nonsense mutation is more serious and occurs when a normal codon specifying an amino acid is 
replaced by a stop codon, which may impact the signaling pathway by prematurely ending 
protein translation; this may result in a nonfunctional protein. A third type of mutation, called 
frameshift mutation, occurs when the insertion or deletion of one or more nucleotides results in 
the disruption of the normal translational reading frame of three nucleotides per codon, to a 
multiple other than three.  This shift can also cause the introduction of a stop codon instead of a 
normal codon, prematurely ending protein translation and compromising gene function (12).  
Any of the above mentioned genetic variations could alter the signaling response of a gene, in 
addition to a signaling pathway, which in the case of mTOR may result in differences among 
individuals in hypertrophy with RET.  
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2.2 THE MTOR SIGNALING PATHWAY 
In humans, skeletal muscle hypertrophy is characterized by an increase in the size of individual 
myofibers.  Hypertrophy is an adaptation to resistive exercise and is the result of an increase in 
protein synthesis (10).  Previous research has shown that the mTOR signaling pathway plays a 
role in the control of cell size (11).  This process can be explained, in part, by this signaling 
pathway’s role in activating proteins needed for protein synthesis. An increase in protein 
synthesis allows new contractile filaments to be added to the muscle fiber, thus increasing its 
size.  RET stimulates the expression of insulin-like growth factor 1 (IGF-1) which has been 
shown to stimulate skeletal muscle hypertrophy by activating the mTOR pathway (13). 
The interaction of insulin and growth factors with their receptors leads to the activation of 
phosphoinositide 3-kinase (PI3K).  PI3K is a lipid kinase; its lipid products provide a site for 
assembling signaling proteins at certain locations in the membrane in response to cell 
stimulation.  PI3K phosphorylates phosphatidylinositol (4,5)-bisphosphate which results in the 
production of phosphatidylinositol-3,4,5-triphosphate [PtdIns(3,4,5)P3 ].  This reaction provides 
a membrane-binding site for two kinases: AKT, a serine-threonine kinase also known as protein 
kinase B (PKB) and phosphoinositide-dependent protein kinase (PDK1)(14). 
PDK1 plays an important role in the mTOR pathway because it phosphorylates and 
activates several key genes which are important for cell growth, proliferation, and survival.  
These genes include AKT, S6 kinase (S6K), p70 S6 kinase (p70s6k, RPS6KB2), and p90 S6 
kinase (RSK) (15).  Song et al. (16) observed that in the hypertrophic muscle of transgenic mice 
over expressing IGF-1, phosphorylation of PDK1 increased by 53%, mTOR by 112% and 
p70S6K by 254%.  These results suggest that over expression of IGF-1 in mice results in 
hypertrophy, with possible mediation from the mTOR signaling pathway.  Variations in PDK1 
 9 
could affect its ability to activate these downstream components of the pathway, compromising 
the physiological processes it helps regulate. 
In order for the catalytic activity of AKT to begin, it must first be phosphorylated by 
PDK1.  AKT lies at the center of the mTOR pathway and its activation regulates genes involved 
in protein synthesis while its inactivation allows the expression of genes known to be associated 
with muscle atrophy, called atrogenes (17).  In humans, there are three forms of AKT, (i.e. 
AKT1-3) encoded by distinct genes, with AKT1 being most active in skeletal muscle (18).  The 
central role that AKT1 plays in skeletal muscle is that of a coordinator of protein synthesis and 
protein degradation, ensuring that the cell manages its energy utilization efficiently (17).  AKT1 
phosphorylation and expression are elevated during muscle hypertrophy and reduced during 
atrophy (11).  Further, more direct evidence, comes from a study involving resistance exercise in 
humans in which AKT1, mTOR, and p70s6k increased significantly in association with protein 
synthesis 1-2 hours post-exercise (19).  Additionally, a 2003 study by Bolster et al. (20) found 
that AKT activation due to exercise was specific to the response generated from RET as opposed 
to other contractile activity such as endurance exercise training.  Despite the compelling 
evidence of an association of AKT1 to protein synthesis and skeletal muscle hypertrophy, there 
is currently a lack of studies investigating associations of SNPs in the AKT1 gene with skeletal 
muscle hypertrophy. 
Experiments in Drosophila melanogaster have suggested that the inhibition of mTOR or 
p70s6k was sufficient to promote decreases in cell size (22).  The mTOR kinase lies in a protein 
complex that brings together two major anabolic components for muscle, the branch-chained 
amino acids and IGFs (23).  The function of mTOR in muscle has been examined by utilizing 
rapamycin, a chemical that binds mTOR (also known as FRAP) and inhibits its function.  
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Activation of mTOR results in an increase in protein translation by activating p70s6k, a positive 
regulator of protein translation.  In addition, mTOR inhibits the activity of eukaryotic translation 
initiation factor 4E binding protein 1 (4EBP1), a negative regulator of protein initiation factor, 
eIF-4E (24).  When skeletal muscle myotubes were treated with rapamycin, in vivo, 
compensatory hypertrophy was completely blocked and p70s6k activation was inhibited (21).  
Recently, research has identified two structurally and functionally distinct mTOR 
containing complexes (25).   The first is the raptor-mTOR complex which mediates cell growth 
through S6K and 4EBP1.  The second and least understood is the rapamycin insensitive rictor-
mTOR complex.  How the rictor-mTOR complex is regulated is not completely understood but it 
is believed to facilitate regulation of AKT by PDK1 (26). Thus, mTOR appears to have a very 
complex and important role in integrating a variety of growth signals, from basic nutritional 
stimulation to activation by protein growth factors, resulting in protein synthesis. 
AMP-activated protein kinase (AMPK) is an important regulator of cellular metabolism 
and is regulated in muscle during exercise (27).  AMPK is a heterotrimeric complex made up of 
a catalytic subunit (AMPKα) and two regulatory subunits (AMPKβ and AMPKγ) (28).  AMPK 
fits into the mTOR signaling pathway through its relationship to AKT and tuberous sclerosis 
complex 2 (TSC2).  Hahn-Windgrassen et al (29) found that AKT inhibits TSC2, a negative 
regulator of mTOR, and activates mTOR by inhibiting the AMPK mediated phosphorylation of 
TSC2.   Winder et al.  (30) have implicated AMPK as being responsible for attenuating the 
anabolic processes that require adenosine tri-phosphate (ATP) and promoting the catabolic 
processes that generate ATP.   
Past research has shown that during an acute bout of resistance exercise, muscle protein 
synthesis appears to be suppressed, it then increases within 2-3 hours post-exercise and remains 
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elevated for 24-48 hours (27).  A 2006 study by Dreyer et al (19), found that a decrease in 
muscle protein synthesis during resistance exercise was associated with an increase in AMPKα2 
(PRKAA2) activity and a decrease in 4E-BP1.  Specifically, these authors found AMPKα2 
activity increased 75% following an acute bout of resistance exercise and 4E-BP1 activity 
decreased by 36%, which may have contributed to the 32% reduction in muscle protein synthesis 
that occurred during resistance exercise in this study.   These findings provide a strong link to 
AMPKα2 activity in skeletal muscle specifically, making it an interesting candidate gene to 
examine for association to skeletal muscle hypertrophy and strength gains following RET. 
Currently there is a lack of research on how specific SNPs in the AMPK gene may be 
associated with skeletal muscle phenotypes, specifically skeletal muscle hypertrophy and 
strength gains following RET.  Therefore it is necessary to look at other investigations involving 
SNPs in the AMPK gene which may be associated with biological processes that could 
contribute to protein synthesis, resulting in skeletal muscle hypertrophy.  Spencer-Jones et al. 
(31) hypothesized that genetic variation in the AMPKα2 gene is associated with the regulation of 
lipid profile, affecting body fat deposition and insulin sensitivity.  These authors found five 
common SNPs in the AMPKα2 gene (rs1124900, rs2796516, rs2746342, rs2796498, and 
rs1418442) which were significantly associated with lower total cholesterol and lower low-
density lipoprotein cholesterol (LDL).  In addition, these authors also found that one AMPKα2 
haplotype was associated with lower total cholesterol and lower LDL cholesterol.  A haplotype is 
a set of SNPs on a single chromatid, or one of two strands of DNA that make up a chromosome.  
If AMPKα2 is indeed associated with the regulation of cholesterol, it is possible that it 
may also be associated with the regulation of the anabolic hormone testosterone.  Cholesterol is 
the major precursor for the synthesis of various steroid hormones, including testosterone. The 
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anabolic effects of testosterone include the growth of muscle mass, increased strength and 
greater bone density.  If increased AMPKα2 activity is associated with lower total and LDL 
cholesterol then it is possible that less substrate is available for the production of testosterone 
under conditions when AMPKα2 activity is stimulated, for instance during RET.  A reduction in 
the amount of testosterone produced by the body could be associated with a reduced potential for 
skeletal muscle growth achieved following RET.  Although these SNPs were associated with 
lower total and LDL cholesterol both individually and as part of a protective haplotype showing 
lower total and LDL cholesterol, their association with muscle hypertrophy and strength 
following RET has yet to be determined.  In addition rs2796516 was also shown to be 
significantly associated with obesity-related variables of total fat (%), central abdominal fat (kg), 
and central fat (%). 
The above mentioned genes are all part of the mTOR signaling pathway.  This complex 
set of reactions follows a signaling pathway which begins with IGF-1 and ends in protein 
translation, resulting in skeletal muscle hypertrophy.  RET produces the stimulus to trigger IGF-
1 and the subsequent cascade of reactions.  Genetic variations in any of the above genes could 
result in variation in the signaling efficacy of this pathway. 
2.3 MERET STUDY 
The Molecular Epidemiology of Resistance Exercise Training (MERET) study was designed to 
examine environmental and genetic contributions to variable muscle responses in young men and 
women.  An investigation using the MERET dataset examined the effects of steroid sulfatase 
(STS) gene variation on circulating levels of the adrenal steroid dehydroepiandrosterone 
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(DHEA) and its sulfated conjugate DHEAS following RET (32).  Results showed that RET 
resulted in significant gains in strength, weight, lean muscle mass and body mass index (BMI) in 
both men and women; as well as a significant decrease in fat percent.  Results also showed that 
participants with the STS “G” allele exhibited greater acute changes in DHEA and the ratio of 
DHEA:DHEAS than those participants with only an STS “A” allele.  These findings suggest that 
RET induced STS activation can be influenced by genetic variations in the STS gene. 
In another study using the MERET dataset, Riechman and colleagues (33) examined the 
association of interleukin-15 (IL-15) protein and IL-15 receptor-α  (IL15RA) genetic variation 
with RET responses.  The IL15RA-Pst1 genotype was associated with significantly greater 
increases in lean muscle mass as well as arm and leg circumference in those participants with an 
A allele.  IL-15 was also shown to be an important mediator in the variability of muscle mass 
gains in response to RET.  More specifically, single nucleotide polymorphisms in exons 4 and 7 
of the IL-15RA gene accounted for a significant proportion of this variability.  Additionally, a 
polymorphism in exon 4 of the IL15RA gene was independently associated with muscle 
hypertrophy following RET.  The above mentioned results suggest that genetic variation is 
associated with variations in muscle mass following RET.  Therefore, the purpose of the present 
investigation is to utilize the MERET dataset to examine possible genetic variations in selected 
genes of the mTOR signaling pathway that could be responsible for the individual variations in 
muscle mass gain following a RET program. 
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2.4 COMPONENTS OF A RET PROGRAM 
The American College of Sports Medicine (ACSM) recommends that RET be performed in an 
individualized, progressive manner in order to achieve optimal results (34).  The ACSM defines 
progression in terms of RET as “the act of moving forward or advancing toward a specific goal.”  
The optimal characteristics of strength-specific programs include both the use of concentric and 
eccentric muscle actions and the performance of both single and multiple joint exercises.  The 
trainable characteristics that can be developed as part of an RET program are muscular strength, 
muscular hypertrophy, muscular power, and muscular endurance.  Based on the goals of the 
participant, RET programs can be individualized to focus on any one, or a combination of, those 
trainable characteristics. 
Progressive overload is the gradual increase in load placed on the body during exercise 
training.  During RET overload may be introduced by increasing the resistance, increasing the 
number of repetitions performed, altering the speed at which repetitions are performed, or by 
increasing the total volume of work performed, in any combination.  RET programs should be 
tailored to meet specific training goals.  Physiological adaptations to training are specific to the 
muscle actions involved (34), speed of movement (34), range of motion (35), muscle groups 
trained (36), energy systems involved (37), and the intensity and volume of training (38, 39).  
RET programs should also change over time in order for the training stimulus to remain optimal.  
Previous research has shown that periodically varying the volume and intensity of a RET 
program is the most effective for long-term progression (40).  
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2.5 RET AND TRAINING HISTORY 
Training history plays an important role in the rate of progression during RET.  The rate of 
strength increase varies considerably between trained and untrained individuals.  Trained 
individuals have much slower rates of improvement (41).  Previous research has shown muscular 
strength increases approximately 40% in untrained, 20% in moderately trained, 16% in trained, 
10% in advanced, and 2% in elite individuals in periods ranging from 4 weeks to 2 years.  
Trained individuals are defined as having approximately six months of consistent RET 
experience.  Advanced individuals are defined as those with years of RET experience who also 
experienced significant improvements in muscular strength.  Elite individuals are athletes who 
are highly trained and have achieved a high level of competition (34).  Previous investigations 
have shown that changes in muscular strength are most prevalent early in training (42, 43).  
Studies using an 11-16 week training period have shown the majority of strength increases 
occurred during the first 4-8 weeks (44, 45).  A study employing a 12 month training period 
showed similar results (43).  It is for this reason RET history (0 hours per week, 0.1-1.8 hours 
per week or >1.8 hours per week during the past year) was chosen as a covariate in this study’s 
analysis of percent change in lean muscle mass, arm muscle quality, and leg muscle quality 
following RET.  
2.6 RET AND HYPERTROPHY 
Numerous types of RET programs have been shown to stimulate muscle hypertrophy in men and 
women (46).  RET programs targeting muscle hypertrophy utilize moderate to heavy loads, are 
 16 
typically high in volume and employ shorter rest periods (47).  These programs have been 
successful because they have been shown to acutely increase testosterone and growth hormone 
levels to a greater degree than high-load, low-volume programs (48).  Traditional strength 
training programs which utilize high-load, low-repetition training, and longer rest periods are 
used to optimize strength gains whereas RET programs that utilize a high-load, high-volume, and 
shorter rest periods have been shown to maximize hypertrophy (49).  The ACSM recommends a 
program which incorporates both concentric and eccentric muscle actions using moderate loads 
(70-85% of 1 repetition maximum) for 8-12 repetitions per set for 1-3 sets per exercise.  The 
ACSM also recommends utilizing both single and multiple joint exercises with 1-2 minutes of 
rest between sets.  RET frequency should be 2-3 days per week (34). 
2.7 RET AND GENDER 
Men have greater muscle size and strength than women, primarily due to greater body size and 
higher levels of anabolic hormones (49).  Previous research comparing the effect of RET on 
muscle development in men and women have concluded that despite similar relative increases in 
strength, absolute muscle hypertrophy resulting form RET has been higher in men than women 
(47).  Cureton et al. (47) found that after 16 weeks of heavy resistance training percent increases 
in strength were greater than percent changes in muscle cross-sectional area (CSA) in both men 
and women, suggesting that strength improvements resulted from a combination of hypertrophic 
and neural adaptations regardless of gender.  Among participants in this study, the relative 
changes in CSA were similar in men and women, although the absolute changes tended to be 
higher in men (46). 
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2.8 RET AND BODY COMPOSITION 
RET has a favorable impact on body composition by increasing fat free mass and decreasing fat 
mass (1).  Fat free mass is the body’s fat free weight and includes the skeleton, water, muscle, 
connective tissue, organ tissues and teeth.  The ideal body fat percentages are generally between 
16% and 25% for women and under 20% for men (1).  RET is also an integral part of weight 
management programs as it increases lean muscle mass.  Lean mass is the most important 
component of resting metabolic rate (RMR); a higher RMR allows a person to expend more 
energy at rest (1). RMR decreases with age as the percentage of fat increases and lean body mass 
decreases.  RET can help slow the age associated decrease in lean body mass by helping to 
preserve muscle mass (1). 
2.9 RET AND AGING 
Previous investigations involving the MERET cohort have noted significant differences in 
percent change in lean muscle mass, percent change in arm muscle quality, and percent change 
in leg muscle quality following RET among those participants who are over the age of 19.5 years 
as opposed to those participants who were under 19.5 years of age (32, 33).  While not fully 
understood, developmental aging may be a possible explanation for the age–related differences 
observed in the muscle phenotype responses to RET in the MERET cohort.  Specifically, there 
could be a variance in the circulating hormone levels of those MERET participants aged 18-19.5 
years versus those MERET participants over the age of 19.5 years.  Hormone levels, specifically 
androgens, can have a direct effect on one’s ability to build lean muscle mass following RET.  It 
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is for this reason, age (<19.5, >19.5 years) will be used as a covariate in all analyses preformed 
in this investigation. 
 
 19 
3.0  METHODS 
3.1 PARTICIPANTS 
154 participants completed 10 weeks of RET (76 men and 78 women).  Eligibility was based 
upon: age between 18 and 31 years, no medical history for disorders involving the 
cardiovascular, endocrine, or skeletal muscle systems, less than three hours RET activity per 
week in the past year, normal caloric consumption and no report of taking anabolic steroids or 
other putative performance enhancing supplements. Medical history was assessed by 
questionnaire (Appendix A) and RET history was assessed using the Modifiable Activity 
Questionnaire (Appendix B).  Participants were instructed not to perform RET activity outside of 
the supervised program and to maintain all other non-RET activities at the same level. After all 
procedures were explained, subjects gave written informed consent prior to participation in the 
study under protocols approved by the University of Pittsburgh Institutional Review Board 
(Informed Consent in Appendix C). 
3.2 PROTOCOL 
Three familiarization-training sessions were conducted prior to the initiation of the program to 
orientate the participants to the equipment and instruct them on how to perform each exercise 
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properly. After these familiarization sessions, one repetition maximums (1 RMs) were 
determined following a warm-up that included three-minutes of exercise on either a treadmill or 
cycle ergometer and static stretching of the shoulders, chest, back, quadriceps, hamstrings and 
calves.  Prior to a 1 RM attempt, subjects performed three repetitions at a weight equivalent to 
50% of the estimated 1 RM. The weight was then increased to 90% of the estimated 1 RM, and 1 
repetition was performed. After 60 seconds of rest, the weight was increased to 100% of the 
estimated 1 RM. Thereafter, successful attempts were followed by attempts made with a higher 
resistance in a manner that minimized the total number of attempts required before the 1 RM 
value was obtained. 
This procedure was performed on all exercise machines used for the RET program in the 
same order for all participants.  The order in which 1 RM exercises were completed was: chest 
press, seated row, lat pull downs, leg extensions, triceps extension, arm curl, shoulder press, 
hamstring curl, low back extension, abdominal crunch and incline press. Leg press and calf 
raises were performed on a Universal leg press machine.  All assessments of 1 RM were 
completed within 4 days of starting and 4 days of completing the RET program. 
3.3 BODY COMPOSITION 
Baseline and post-RET measures were obtained for the following: height (wall-mounted 
stadiometer), weight (Detecto Clinical scale), body composition by hydrostatic weighing (50), 
and circumference measurements of arms and thighs. Residual lung volume was estimated prior 
to the hydrostatic weighing assessments according to tables derived from formulas based on the 
participant’s height and age (51, 52).  Participants wore a bathing suit during these assessments 
 21 
which were administered within 2-4 days of starting or completing the RET program.  Trials 
were performed until three valid underwater weight measurements were achieved.  Valid 
measurements were defined as those that were within the margin of error of the computer 
software program.  The mean of these three underwater weight measurements was then 
determined and percent body fat was calculated according to the formula of Siri (50).  
Arm circumference was measured on the right side of the body at the middle of the bicep 
with the arm relaxed at the side of the body. Thigh circumference was measured on the right side 
of the body at the midpoint of the femur with the participant in the standing position.  All 
circumferences were measured using a Gullick measuring tape.  Duplicate measures were made 
of each circumference and recorded to the nearest 0.1 cm, an average of these two measures was 
then calculated.  All measurements were recorded on a data collection form (Appendix D).   
3.4 RET PROGRAM 
The ten-week, three sessions per week RET program included 13 exercises encompassing all 
major muscle groups with weights set at 80% of 1 RM. These sessions were supervised by 
exercise physiologists (participant to trainer ratio 2:1 to 3:1). The RET program included the 
following exercises performed in the following order on the StriveTM (Canonsburg, PA) weight 
machines: chest press, seated row, lat pull downs, leg extensions, triceps extension, arm curl, 
shoulder press, hamstring curl, low back extension, abdominal crunch and incline press.  Leg 
press and calf raises were performed on a Universal leg press machine.   
A warm up consisting of exercise on either a treadmill or stationary bike for five minutes 
followed by stretching of all major muscle groups was performed before each day of RET.  The 
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stretches included the shoulders, chest, back, quadriceps, hamstrings and calves.  Participants 
performed 3 sets of 6-10 repetitions for each exercise. Participants were given thirty seconds of 
rest between each set and one minute between exercises. Workout charts for recording resistance 
and number of repetitions completed for each weight machine were given to each participant.  In 
order to maintain the relative difficulty at the same level for all participants throughout the study, 
resistance settings were increased when participants were able to complete 10 repetitions on a 
particular set.  
3.5 GENE SELECTION 
Appendix E contains all genes from the mTOR pathway for which SNPs, with at least two 
known genotypes with a frequency over 15%, were available using the publicly available 
database hapmap.org.  SNPs are listed by reference SNP number (rs), genotype frequency from 
reference homozygotes, heterozygotes and other homozygotes, as well as allele frequency data 
for the reference allele and other allele.  This reference data was taken from Utah residents with 
ancestry from northern and western Europe which best reflects most MERET subjects.  
While the current literature shows how the genes of the mTOR signaling pathway may 
influence skeletal muscle hypertrophy, the literature is lacking on which particular SNPs may 
influence this outcome, either positively or negatively, following RET.  Therefore it was 
necessary to choose those genes, which based on the current literature, have the highest potential 
to be associated with skeletal muscle hypertrophy and strength gains following RET.  It was then 
necessary to choose SNPs from those genes which are common in most individuals based on the 
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current literature and the genotype and allele frequency data presented in Appendix F and may 
have the highest potential to be associated with skeletal muscle strength and hypertrophy.  
When examining the mTOR signaling pathway for potential candidate genes for this 
study of genetic variability in muscle response to RET, the literature made an especially strong 
case for several genes; mTOR, p70s6k, PDPK1, AKT1, and AMPKα2.  The mTOR gene is an 
interesting candidate because its inhibition has been linked to decreases in cell size (22).  
Furthermore, mTOR activates p70s6k, a positive activator of protein translation (21).  The mTOR 
gene was not chosen for this investigation due to its large size, it has 23 known SNPs and the 
mTOR containing complexes RICTOR and RAPTOR have 14 and 63 respectively (Appendix E).  
Since mTOR was not chosen to be examined in this investigation p70s6k was disqualified as well, 
due to the fact that the interaction between these two genes could not be evaluated.   
PDPK1 was another very interesting candidate gene considered for this study.  PDPK1 
has a vital role in the mTOR signaling pathway as it phosphorylates several genes related to cell 
growth and proliferation; AKT1, S6K, p70s6k, and RSK (15).  It is quite possible that any 
variations in this gene could affect the efficacy of the mTOR signaling pathway.  The reason 
PDPK1 was not chosen for this study was that it has only two known SNPs that lie in very close 
proximity to one another on the gene, which makes it difficult to get a true representation of their 
affect on the function of this gene (Appendix E).  Therefore, AKT1 and AMPKα2 were chosen 
to be examined for possible association to lean muscle mass and muscle strength gains following 
RET in the MERET cohort.  
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3.5.1 AKT 1 
AKT1 was selected for this investigation because of the important role this gene appears to play 
among the intracellular signaling mechanisms controlling protein synthesis, which leads to 
skeletal muscle hypertrophy (11, 13, 21).  In the present investigation, four common SNPs that 
span the AKT1 gene will be examined for possible associations to skeletal muscle hypertrophy 
and strength gains following RET in the MERET study.   Table 1 contains the AKT1 SNPs 
selected for this investigation.  SNPs are listed by reference SNP number (rs), genotype 
frequency from reference homozygotes, heterozygotes and other homozygotes, as well as allele 
frequency data for the reference allele and other allele as found in the genetic database 
hapmap.org.  This reference dataset was obtained from Utah residents with ancestry from 
northern and western Europe which best reflects most MERET subjects. 
3.5.2 AMPKα2 
The AMPKα2 gene was selected for this investigation because of the interactions it has with the 
AKT1 gene in the mTOR signaling pathway and the vital role it plays as a key regulator of 
whole body metabolism (27).  For the purposes of this investigation, the possible association of 
three common AMPKα2 SNPs (rs1124900, rs2796516 and rs1418442) with muscle hypertrophy 
and strength gains following RET in the MERET study will be examined. Table 1 contains the 
AMPKα2 SNPs selected for this investigation.  SNPs are listed by reference SNP number (rs), 
genotype frequency from reference homozygotes, heterozygotes and other homozygotes, as well 
as allele frequency data for the reference allele and other allele as found in the genetic database 
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hapmap.org.  This reference dataset was obtained from Utah residents with ancestry from 
northern and western Europe which best reflects most MERET subjects. 
Table 1 Genes and SNPs of the mTOR Signaling Pathway selected for this investigation 
Gene SNP RS # Reference- 
Homozygote
Reference- 
Heterozygote
Other- 
Heterozygote
Reference-  
Allele 
Other- 
Allele 
AKT 1 rs2494735 
rs1130233 
rs3001371 
rs1130214 
A/A (0.414) 
G/G (0.677) 
C/C (0.467) 
G/G (0.517) 
A/G (0.517) 
A/G (0.258) 
C/T (0.417) 
G/T (0.417) 
G/G (0.069) 
A/A (0.065) 
T/T (0.117) 
T/T (0.067) 
A (0.672) 
G (0.806) 
C (0.675) 
G (0.725) 
G (0.328)
A (0.194) 
T (0.325) 
T (0.275) 
AMPK α 2 rs1124900 
rs2796516 
rs1418442 
T/T (0.300) 
G/G (0.737) 
A/A (0.367) 
G/T (0.533) 
A/G (0.193) 
A/G (0.500) 
G/G (0.167) 
A/A (0.070) 
G/G (0.133) 
T (0.567) 
G (0.833) 
A (0.617) 
G (0.433)
A (0.167) 
G (0.383)
3.6 GENETIC ANALYSIS 
Blood samples were collected in 10-ml EDTA anticoagulant vials (Vacutainer) immediately 
before and after the first and last RET sessions.  Samples were immediately placed on ice and 
were subsequently centrifuged at 1,200 g for 25 minutes.  Plasma was collected and stored at -
70°C in 1-ml aliquots.  Genomic DNA was isolated from the white blood cells of these samples 
using standard methods (53).  DNA fragments surrounding the chosen SNPs of the AKT1 and 
AMPKα2 genes were amplified using standard polymerase chain reaction (PCR) methods.  
Detection of each participant’s genetic variation was conducted using either restriction fragment 
length polymorphism analysis (RFLP), or fluorescence polarization (FP), according to the nature 
of the specific genetic variation.  A Peltier PTC-100 Thermal Cycler (MJ Research, Waltham, 
MA) was used for all PCR and FP reactions requiring the use of a thermal-cycler. 
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3.6.1 rs2494735 (AKT1)   
Amplification of each participant’s genomic DNA was performed using a PCR reaction.  The 25-
µl per sample final reaction volume containing 1.3µl of DNA consisted of 2.5µl of 10x PCR 
buffer, 0.75µl MgCl2, 4.0µl deoxyribonucleotide triphosphate (DNTP) mixture, 0.375µl of 
forward primer: gttcctgctgagttaggg, 0.375µl of reverse primer: ctccgagtcaggtagtc, 0.1µl of Taq 
DNA polymerase, and 16.9µl of dH2O.   The reaction mixture was held in the thermal-cycler at 
95°C for 5 minutes followed by 35 cycles of 95°C for 30 seconds, 54°C for 15 seconds and 72°C 
for 30 seconds, followed by 72°C for 5 minutes.  FP was then used to determine each 
participant’s genotype using the following procedures.  The first step of FP involves the removal 
of unincorporated primers and dNTPs from the PCR product and was accomplished in the 
following manner.  Following the PCR reaction, 10µl of an enzymatic mixture containing 1µl of 
shrimp alkaline phosphatase, 1µl of shrimp alkaline phosphatase buffer, 0.1µl of Escherichia 
coli exonuclease I, and 7.9µl of dH2O was added to 10-µl  PCR product.  The mixture was 
incubated in the thermal-cycler at 37°C for 90 minutes before the enzymes were heat inactivated 
at 95°C for 15 minutes.   
The third step of FP is a single base extension reaction and was accomplished in the 
following manner.  The samples from the previous step were added to a 10µl cocktail containing 
1µl of thermosequanase buffer, 1µl of internal primer: cttccacctgtcccggga, 0.05µl of allele-
specific dye-labeled dideoxy-NTP, 0.1µl of thermosequanase, and 7.85µl of dH2O.  These 
samples were then incubated in the thermal-cycler for 94°C for 1 minute followed by 40 cycles 
of 94°C for 10 seconds and 52°C for 30 seconds then at 72°C for 10 minutes.  FP measurement 
was then performed on a LJL Analyst HT fluorescence reader (LJL Biosystems, Sunnyvale, CA) 
controlled by LJL Criterion software.  The average FP value was then compared with the 
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negative control samples using AlleleCaller software (LJL Biosystems).  Subjects were then 
genotyped for the SNP rs2494735 (AKT1) as either AA, AG, or GG.    
3.6.2 rs1130233 (AKT1) 
Amplification of each participant’s genomic DNA was performed using a PCR reaction.  The 25-
µl per sample final reaction volume containing 1.3µl of DNA consisted of 2.5µl of 10x PCR 
buffer, 0.75µl MgCl2, 4.0µl deoxyribonucleotide triphosphate (DNTP) mixture, 0.375µl of 
forward primer: caccttcatcatccgctg, 0.375µl of reverse primer: gactgggccagtttccaa, 0.1µl of Taq 
DNA polymerase, and 16.9µl of dH2O.   The reaction mixture was held in the thermal-cycler at 
95°C for 5 minutes followed by 35 cycles of 95°C for 30 seconds, 54°C for 15 seconds and 72°C 
for 30 seconds, followed by 72°C for 5 minutes.  FP was then used to determine each 
participant’s genotype using the following procedures.  Following the PCR reaction, 10µl of an 
enzymatic mixture containing 1µl of shrimp alkaline phosphatase, 1µl of shrimp alkaline 
phosphatase buffer, 0.1µl of Escherichia coli exonuclease I, and 7.9µl of dH2O was added to 10-
µl  PCR product.  The mixture was incubated in the thermal-cycler at 37°C for 90 minutes before 
the enzymes were heat inactivated at 95°C for 15 minutes.  The samples from the previous step 
were added to a 10µl cocktail containing 1µl of thermosequanase buffer, 1µl of internal primer: 
ggcggccaggccaggc, 0.05µl of allele-specific dye-labeled dideoxy-NTP, 0.1µl of 
thermosequanase, and 7.85µl of dH2O.  These samples were then incubated in the thermal-cycler 
for 94°C for 1 minute followed by 40 cycles of 94°C for 10 seconds and 52°C for 30 seconds 
then at 72°C for 10 minutes.  FP measurement was then performed on a LJL Analyst HT 
fluorescence reader (LJL Biosystems, Sunnyvale, CA) controlled by LJL Criterion software.  
The average FP value was then compared with the negative control samples using AlleleCaller 
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software (LJL Biosystems).  Subjects were then genotyped for the SNP rs1130233 (AKT1) as 
either GG, AG, or AA. 
3.6.3 rs3001371 (AKT1) 
Amplification of each participant’s genomic DNA was performed using a PCR reaction.  The 25-
µl per sample final reaction volume containing 1.3µl of DNA consisted of 2.5µl of 10x PCR 
buffer, 0.75µl MgCl2, 4.0µl deoxyribonucleotide triphosphate (DNTP) mixture, 0.375µl of 
forward primer: atgttggcaggctagtctcaactc, 0.375µl of reverse primer: gtgctcccaggccctcctcag, 
0.1µl of Taq DNA polymerase, and 16.9µl of dH2O.  The reaction mixture was held in the 
thermal-cycler at 95°C for 5 minutes followed by 35 cycles of 95°C for 30 seconds, 56°C for 15 
seconds and 72°C for 30 seconds, followed by 72°C for 5 minutes.  .FP was then used to 
determine each participant’s genotype using the following procedures.  Following the PCR 
reaction, 10µl of an enzymatic mixture containing 1µl of shrimp alkaline phosphatase, 1µl of 
shrimp alkaline phosphatase buffer, 0.1µl of Escherichia coli exonuclease I, and 7.9µl of dH2O 
was added to 10-µl  PCR product.  The mixture was incubated in the thermal-cycler at 37°C for 
90 minutes before the enzymes were heat inactivated at 95°C for 15 minutes.  The samples from 
the previous step were added to a 10µl cocktail containing 1µl of thermosequanase buffer, 1µl of 
internal primer: cagcctcagtttccccacccaaacccca, 0.05µl of allele-specific dye-labeled dideoxy-
NTP, 0.1µl of thermosequanase, and 7.85µl of dH2O.  These samples were then incubated in the 
thermal-cycler at 94°C for 1 minute followed by 40 cycles of 94°C for 10 seconds and 52°C for 
30 seconds then at 72°C for 10 minutes.  FP measurement was then performed on a LJL Analyst 
HT fluorescence reader (LJL Biosystems, Sunnyvale, CA) controlled by LJL Criterion software.  
The average FP value was then compared with the negative control samples using AlleleCaller 
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software (LJL Biosystems).  Subjects were then genotyped for the SNP rs3001371 (AKT1) as 
either CC, CT, or TT.  
3.6.4 rs1130214 (AKT1)  
Amplification of each participant’s genomic DNA was performed using a PCR reaction.  The 25-
µl per sample final reaction volume containing 1.3µl of DNA consisted of 2.5µl of 10x PCR 
buffer, 0.75µl MgCl2, 4.0µl deoxyribonucleotide triphosphate (DNTP) mixture, 0.375µl of 
forward primer: tgctcctcactgacggacttgtct, 0.375µl of reverse primer: cat gaggaagacaggaccagg 
atg, 0.1µl of Taq DNA polymerase, and 16.9µl of dH2O.  The reaction mixture was held in the 
thermal-cycler at 95°C for 5 minutes followed by 35 cycles of 95°C for 30 seconds, 58°C for 15 
seconds and 72°C for 30 seconds, followed by 72°C for 5 minutes.  RFLP analysis was used to 
determine each participant’s genotype using the following procedures.  Amplified PCR-product 
(15µl) was added to 5µl cocktail that contained 1µl of the restriction enzyme XcmI, 2µl of NE 
Buffer and 2µl of dH2O; then incubated overnight at 37°C.  Each digested sample was then 
loaded onto a 2.0% agarose gel containing ethidium bromide and electrophoresed for 2 hours at 
120 volts.  After electrophoresis, the DNA fragments were visualized by ultraviolent illumination 
(Eagle Eye), and fragment sizes were estimated by comparison to a 1-kb ladder run on the same 
gel.  The presence of a polymorphic restriction site (XcmI) at the rs1130214 (AKT1) locus is 
specified as G base, whereas the absence of this site is a T base.  Participants were then 
categorized as exhibiting GG, GT, or TT.  
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3.6.5 rs1124900 (AMPKα2) 
Amplification of each participant’s genomic DNA was performed using a PCR reaction.  The 25-
µl per sample final reaction volume containing 1.3µl of DNA consisted of 2.5µl of 10x PCR 
buffer, 0.75µl MgCl2, 4.0µl deoxyribonucleotide triphosphate (DNTP) mixture, 0.375µl of 
forward primer: cagactgcctacccagca ttt ct, 0.375µl of reverse primer: gaggatttgaggctgaggaggtc, 
0.1µl of Taq DNA polymerase, and 16.9µl of dH2O.  The reaction mixture was held in the 
thermal-cycler at 95°C for 5 minutes followed by 35 cycles of 95°C for 30 seconds, 50°C for 15 
seconds and 72°C for 30 seconds, followed by 72°C for 5 minutes.  FP was then used to 
determine each participant’s genotype using the following procedures.  Following the PCR 
reaction, 10µl of an enzymatic mixture containing 1µl of shrimp alkaline phosphatase, 1µl of 
shrimp alkaline phosphatase buffer, 0.1µl of Escherichia coli exonuclease I, and 7.9µl of dH2O 
was added to 10-µl  PCR product.  The mixture was incubated at 37°C for 90 minutes before the 
enzymes were heat inactivated at 95°C for 15 minutes.  The samples from the previous step were 
added to a 10µl cocktail containing 1µl of thermosequanase buffer, 1µl of internal primer: att ctg 
gagagaaggcaggttaattaaatc, 0.05µl of allele-specific dye-labeled dideoxy-NTP, 0.1µl of 
thermosequanase, and 7.85µl of dH2O.  These samples were then incubated in the thermal-cycler 
at 94°C for 1 minute followed by 40 cycles of 94°C for 10 seconds and 52°C for 30 seconds then 
at 72°C for 10 minutes.  FP measurement was then performed on a LJL Analyst HT fluorescence 
reader (LJL Biosystems, Sunnyvale, CA) controlled by LJL Criterion software.  The average FP 
value was then compared with the negative control samples using AlleleCaller software (LJL 
Biosystems).  Subjects were then genotyped for the SNP rs3001371 (AKT1) as either TT, GT, or 
GG. 
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3.6.6 rs2796516 (AMPKα2) 
Amplification of each participant’s genomic DNA was performed using a PCR reaction.  The 25-
µl per sample final reaction volume containing 1.3µl of DNA consisted of 2.5µl of 10x PCR 
buffer, 0.75µl MgCl2, 4.0µl deoxyribonucleotide triphosphate (DNTP) mixture, 0.375µl of 
forward primer: ctgttggttataatacttgggagtg, 0.375µl of reverse primer: aggtgctcaatatcatgggtcatc, 
0.1µl of Taq DNA polymerase, and 16.9µl of dH2O.  The reaction mixture was held in the 
thermal-cycler at 95°C for 5 minutes followed by 35 cycles of 95°C for 30 seconds, 48°C for 15 
seconds and 72°C for 30 seconds, followed by 72°C for 5 minutes.  RFLP analysis was used to 
determine each participant’s genotype using the following procedures.  Amplified PCR-product 
(15µl) was added to 5µl cocktail that contained 1µl of the restriction enzyme MnlI, 2µl of NE 
Buffer and 2µl of dH2O; then incubated overnight at 37°C.  Each digested sample was then 
loaded onto a 2.0% Agarose gel containing ethidium bromide and electrophoresed for 2 hours at 
120 volts.  After electrophoresis, the DNA fragments were visualized by ultraviolent illumination 
(Eagle Eye), and fragment sizes were estimated by comparison to a 1-kb ladder run on the same 
gel.  The presence of a polymorphic restriction site (MnlI) at the rs2796516 (PRKAA2) locus is 
specified as G base, whereas the absence of this site is a A base.  Participants were then 
categorized as exhibiting GG, AG, or AA.  
3.6.7 rs1418442 (AMPKα2) 
Amplification of each participant’s genomic DNA was performed using a PCR reaction.  The 25-
µl per sample final reaction volume containing 1.3µl of DNA consisted of 2.5µl of 10x PCR 
buffer, 0.75µl MgCl2, 4.0µl deoxyribonucleotide triphosphate (DNTP) mixture, 0.375µl of 
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forward primer: gcccatctggtttctaattacag, 0.375µl of reverse primer: tcaagtcctggatcctccatatatc, 
0.1µl of Taq DNA polymerase, and 16.9µl of dH2O.  The reaction mixture was held in the 
thermal-cycler at 95°C for 5 minutes followed by 35 cycles of 95°C for 30 seconds, 48°C for 15 
seconds and 72°C for 30 seconds, followed by 72°C for 5 minutes.  RFLP analysis was used to 
determine each participant’s genotype using the following procedures.  Amplified PCR-product 
(15µl) was added to 5µl cocktail that contained 1µl of the restriction enzyme SfaNI, 2µl of NE 
Buffer and 2µl of dH2O; then incubated overnight at 37°C.  Each digested sample was then 
loaded onto a 2.0% Agarose gel containing ethidium bromide and electrophoresed for 2 hours at 
120 volts.  After electrophoresis, the DNA fragments were visualized by ultraviolent illumination 
(Eagle Eye), and fragment sizes were estimated by comparison to a 1-kb ladder run on the same 
gel.  The presence of a polymorphic restriction site (SfaNI) at the rs1418442 (PRKAA2) locus is 
specified as A base, whereas the absence of this site is a G base.  Participants were then 
categorized as exhibiting AA, AG, or GG.  
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3.7 STATISTICAL ANALYSIS 
SPSS software (SPSS Inc., Chicago, IL, v11.5) was used for all analyses. One-way analysis of 
variance (ANOVA) was used to analyze differences in baseline characteristics of the 
participants’ individual genetic constitution, or genotype. Chi-square analysis was used to 
determine if the frequencies of the genotypes were in Hardy-Weinberg equilibrium.  Hardy-
Weinberg equilibrium is the principle of ‘genetic equilibrium’ that exists between the frequency 
of alleles and the genotype of the population.  Genetic equilibrium is the foundation of 
population genetics.  In previous studies using the MERET dataset, Riechman and colleagues 
(32, 33) found significant percent gains in muscle mass and strength based on participants 
gender, age, and RET history.  Therefore, analysis of covariance (ANCOVA) was used to control 
for differences in the relative percent change in lean muscle mass and the percent change in 
mass-adjusted strength to RET by genotype, with reference to gender, age (<19.5 years or >19.5 
years) and RET history (0 hours per week, 0.1-1.8 hours per week or >1.8 hours per week during 
the past year). 
Percent gains will be calculated as 100 x (postmeasurement – premeasurement) 
/premeasurement.  Arm mass-adjusted strength was calculated as [1 RM biceps (kg) + 1 RM 
triceps (kg)/arm circumference (cm)].  Leg mass-adjusted strength was calculated as [1 RM 
hamstring curl (kg) + 1 RM leg extension (kg)/thigh circumference (cm)]. 
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4.0  RESULTS 
4.1 PARTICIPANTS 
The baseline characteristics of the MERET cohort are presented in Table 2.  Of these 
participants, 14 (9.3%) of those who completed the RET were not Caucasian (i.e. African 
American, Hispanic, Asian).  In all, 28 men and 28 women were non-compliant with the RET 
and were excluded from the study.  Non-compliance was defined as the inability to complete 30 
RET sessions in 10 weeks.  If participants missed a scheduled session, a make-up session was 
arranged.  In order to prevent the same muscle being exercised on consecutive days, make-up 
sessions included split workouts in which participants completed 5 sets of upper and lower body 
exercises on consecutive days.  Participants were limited to five split workouts before they were 
excluded.     
 
 
 
 
 
 
 
 35 
Table 2 Baseline Characteristics of the MERET Cohort 
Men/Women (n) 76 / 78 
Age (years) 20.9 ± 2.5 
Height (cm) 170.5 ± 9.0 
Weight (km) 73.0 ± 15.2 
Fat (%) 22.8 ± 7.4 
Lean Mass (kg) 56.1 ± 11.7 
Activity history (hrs-wk) 6.3 ± 8.7 
RET history (hrs-wk) 1.0 ± 1.6 
Values for age, height, weight, fat %, lean mass, activity history, and 
RET history are means ± SD 
 
Of the 154 MERET participants who completed RET, not all participants were able to be 
genotyped for the seven SNPs chosen for this investigation, despite several attempts.  The total N 
varied by SNP and ranged from 115 to 121 participants (75-79%).  Participant characteristics by 
genotype for each of the 7 SNPs chosen for this investigation are presented in Tables 3-9.  
Frequencies of all genotypes presented were in Hardy-Weinberg equilibrium and did not differ 
between gender and race categories (P > 0.05).   
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Table 3 Participant Characteristics by rs2494735 (AKT 1) Genotype 
 AA AG GG P-value 
Men/Women (n) 21/23 30/29 8/8 0.95 
Age (years) 21.4±3.2 20.7±2.1 20.7±2.0 0.34 
Height (cm) 170.1±9.4 170.4±8.2 172.2±8.9 0.70 
Weight (kg) 72.4±16.7 72.9±13.8 77.2±13.9 0.52 
Fat (%) 22.1±7.4 22.4±8.1 25.9±8.8 0.24 
Lean mass (kg) 55.9±11.9 56.2±11.0 56.7±9.5 0.97 
Act. history   
(hrs-wk) 
6.3±6.2 5.7±5.6 3.2±2.0 0.15 
RET history  
(hrs-wk) 
1.1±1.7 1.0±1.7 0.4±0.6 0.33 
Values are means ± SD.  Frequencies of genotypes are in Hardy-Weinberg equilibrium  
and are similar between gender and race (P > 0.05). 
Table 4 Participant Characteristics by rs1130233 (AKT 1) Genotype 
 GG AG AA P-value 
Men/Women (n) 35/29 20/28 4/4 0.40
Age (years) 21.3±3.0 20.7±2.1 20.5±1.9 0.42
Height (cm) 170.6±9.0 169.9±8.3 173.7±8.0 0.51
Weight (kg) 72.7±15.2 73.7±14.6 75.5±14.4 0.85
Fat (%) 21.5±7.6 24.4±8.3 25.2±6.3 0.11
Lean mass (kg) 56.7±11.4 55.3±10.7 56.3±11.3 0.80
Act. history   
(hrs-wk) 
5.5±5.5 5.4±4.6 4.1±2.7 0.74
RET history  
(hrs-wk) 
1.0±1.5 0.9±1.6 1.2±2.0 0.87
Values are means ± SD.  Frequencies of genotypes are in Hardy-Weinberg equilibrium  
and are similar between gender and race (P > 0.05). 
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Table 5 Participant Characteristics by rs3001371 (AKT 1) Genotype 
 CC CT TT P-value 
Men/Women (n) 28/27 21/23 11/11 0.95
Age (years) 21.2±3.0 21.0±2.1 20.5±2.3 0.55
Height (cm) 170.4±9.1 169.7±8.1 172.5±8.6 0.46
Weight (kg) 72.5±15.8 72.1±14.8 77.7±14.9 0.30
Fat (%) 21.8±7.4 22.1±8.1 26.4±8.3 0.06
Lean mass (kg) 56.4±11.7 55.7±11.2 56.9±9.4 0.91
Act. history   
(hrs-wk) 
5.8±5.8 6.4±6.0 3.5±2.6 0.12
RET history  
(hrs-wk) 
1.1±1.6 1.2±2.0 0.4±0.5 0.17
Values are means ± SD.  Frequencies of genotypes are in Hardy-Weinberg equilibrium  
and are similar between gender and race (P > 0.05). 
Table 6 Participant Characteristics by rs1130214 (AKT 1) Genotype 
 GG GT TT P-value 
Men/Women (n) 33/22 23/30 4/9 0.80
Age (years) 21.0±2.6 21.0±2.7 21.0±2.3 0.99
Height (cm) 171.4±9.5 169.9±7.6 169.8±7.0 0.65
Weight (kg) 76.2±17.2 71.1±12.3 70.1±12.5 0.15
Fat (%) 22.8±7.7 22.1±8.4 24.7±6.8 0.57
Lean mass (kg) 58.1±11.5 55.2±10.2 52.7±10.6 0.18
Act. history   
(hrs-wk) 
5.7±5.2 6.0±6.3 3.7±2.6 0.41
RET history  
(hrs-wk) 
0.9±1.2 1.1±1.9 1.0±2.4 0.81
Values are means ± SD.  Frequencies of genotypes are in Hardy-Weinberg equilibrium  
and are similar between gender and race (P > 0.05). 
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Table 7 Participant Characteristics by rs1124900 (AMPKα2) Genotype 
 TT GT GG P-value 
Men/Women (n) 17/16 28/28 15/16 0.97
Age (years) 21.4±3.4 20.8±2.3 21.0±2.2 0.54
Height (cm) 168.5±9.3 171.2±8.2 171.6±8.5 0.25
Weight (kg) 73.1±14.9 73.0±15.5 73.8±14.5 0.97
Fat (%) 22.7±6.5 22.6±8.9 22.6±7.4 0.99
Lean mass (kg) 56.3±11.6 56.0±10.9 56.8±11.1 0.94
Act. history   
(hrs-wk) 
4.4±3.2 5.3±5.2 7.1±7.2 0.14
RET history  
(hrs-wk) 
0.6±0.9 1.0±1.8 1.3±2.0 0.30
Values are means ± SD.  Frequencies of genotypes are in Hardy-Weinberg equilibrium  
and are similar between gender and race (P > 0.05). 
Table 8 Participant Characteristics by rs2796516 (AMPKα2) Genotype 
 GG AG AA P-value 
Men/Women (n) 40/45 18/15 1/0 0.46 
Age (years) 20.9±2.5 21.6±2.8 18.0 0.19 
Height (cm) 171.1±8.6 169.4±8.6 173.5 0.60 
Weight (kg) 73.7±14.8 71.1±14.1 106.0 0.06 
Fat (%) 23.0±7.7 21.6±8.4 30.4 0.42 
Lean mass (kg) 56.3±11.2 55.4±10.5 73.7 0.26 
Act. history   
(hrs-wk) 
5.9±6.0 4.4±3.7 5.0 0.41 
RET history  
(hrs-wk) 
1.0±1.6 1.0±1.8 0.8 0.97 
Values are means ± SD.  Frequencies of genotypes are in Hardy-Weinberg equilibrium  
and are similar between gender and race (P > 0.05). 
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Table 9 Participant Characteristics by rs1418442 (AMPKα2) Genotype 
 AA AG GG P-value 
Men/Women (n) 15/19 33/28 9/11 0.59
Age (years) 21.0±2.9 21.0±2.5 21.0±2.5 0.99
Height (cm) 169.1±8.8 170.8±7.9 171.4±9.9 0.55
Weight (kg) 71.8±14.5 72.4±15.2 76.0±16.2 0.58
Fat (%) 22.3±6.5 22.7±8.5 23.1±7.7 0.93
Lean mass (kg) 55.7±11.6 55.5±10.6 58.1±11.6 0.65
Act. history   
(hrs-wk) 
4.6±3.6 6.2±6.6 6.0±5.1 0.42
RET history  
(hrs-wk) 
0.6±0.9 1.1±1.8 1.0±1.3 0.33
Values are means ± SD.  Frequencies of genotypes are in Hardy-Weinberg equilibrium  
and are similar between gender and race (P > 0.05). 
4.2 MUSCLE PHENOTYPE RESPONSES TO RET 
Muscle phenotype responses of the MERET cohort to RET by SNP are presented in Tables 10-
16.  Percent change in lean muscle mass, percent change in arm mass-adjusted strength, and 
percent change in leg mass-adjusted strength are presented as means ± the standard error of the 
estimate.  The covariates used in each statistical model were gender, age (<19.5 years or >19.5 
years) and RET history (0 hours per week, 0.1-1.8 hours per week or >1.8 hours per week during 
the past year).  
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Table 10 Muscle Phenotype Responses to RET by rs2494735 Genotype. 
 AA AG GG 
Lean muscle mass gain, % 1.951 ± 0.502 2.601 ± 0.418 3.370 ± 0.807 
Arm mass-adjusted strength gain,% 39.197 ± 3.175 39.548 ± 2.645 31.331 ± 5.099
Leg mass-adjusted strength gain, % 39.614 ± 3.268 34.567 ± 2.722 36.244 ± 5.248
Values are means ± SE.  Arm mass-adjusted strength = (1 RM biceps + 1 RM triceps) / 
arm circumference.  Leg mass-adjusted strength = (1 RM hamstring curl + 1 RM leg 
extension) / thigh circumference.  P > 0.05 for genotype (analysis of covariance). 
 
Table 11 Muscle Phenotype Responses to RET by rs1130213 Genotype. 
 GG AG AA 
Lean muscle mass gain, % 2.399 ± 0.415 2.559 ± 0.468 2.744 ± 1.142 
Arm mass-adjusted strength gain, % 40.137 ± 2.797 38.786 ± 3.155 36.050 ± 7.700
Leg mass-adjusted strength gain, % 37.463 ± 2.733 37.708 ± 3.084 30.610 ± 7.526
Values are means ± SE.  Arm mass-adjusted strength = (1 RM biceps + 1 RM triceps) / 
arm circumference.  Leg mass-adjusted strength = (1 RM hamstring curl + 1 RM leg 
extension) / thigh circumference.  P > 0.05 for genotype (analysis of covariance). 
 
Table 12 Muscle Phenotype Responses to RET by rs3001371 Genotype. 
 CC CT TT 
Lean muscle mass gain, % 2.334 ± 0.443 2.037 ± 0.485 3.496 ± 0.689 
Arm mass-adjusted strength gain, % 39.694 ± 3.034 39.474 ± 3.319 35.559 ± 4.720
Leg mass-adjusted strength gain, % 38.668 ± 2.888 39.516 ± 3.159 28.471 ± 4.493
Values are means ± SE.  Arm mass-adjusted strength = (1 RM biceps + 1 RM triceps) / 
arm circumference.  Leg mass-adjusted strength = (1 RM hamstring curl + 1 RM leg 
extension) / thigh circumference.  P > 0.05 for genotype (analysis of covariance). 
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Table 13 Muscle Phenotype Responses to RET by rs1130214 Genotype. 
 GG GT TT 
Lean muscle mass gain, % 2.005 ± 0.445 2.706 ± 0.446 2.941 ± 0.898 
Arm mass-adjusted strength gain, % 40.542 ± 2.852 36.539 ± 2.858 35.116 ± 5.749
Leg mass-adjusted strength gain, % 38.722 ± 2.943 35.795 ± 2.949 34.497 ± 5.934
Values are means ± SE.  Arm mass-adjusted strength = (1 RM biceps + 1 RM triceps) / 
arm circumference.  Leg mass-adjusted strength = (1 RM hamstring curl + 1 RM leg 
extension) / thigh circumference.  P > 0.05 for genotype (analysis of covariance). 
 
Table 14 Muscle Phenotype Responses to RET by rs1124900 Genotype. 
 TT GT GG 
Lean muscle mass gain, % 2.188 ± 0.577 2.757 ± 0.432 2.286 0.581 
Arm mass-adjusted strength gain, % 42.046 ± 3.893 35.680 ± 2.913 41.976 ± 3.923
Leg mass-adjusted strength gain, % 37.408 ± 3.846 37.723 ± 2.878 35.644 ± 3.875
Values are means ± SE.  Arm mass-adjusted strength = (1 RM biceps + 1 RM triceps) / 
arm circumference.  Leg mass-adjusted strength = (1 RM hamstring curl + 1 RM leg 
extension) / thigh circumference.  P > 0.05 for genotype (analysis of covariance). 
 
Table 15 Muscle Phenotype Responses to RET by rs2796516 Genotype. 
 GG AG AA * 
Lean muscle mass gain, % 2.440 ± 0.351 2.447 ± 0.594 4.394 ± 3.278 
Arm mass-adjusted strength gain, % 39.008 ± 2.361 36.655 ± 4.005 80.087 ± 22.083
Leg mass-adjusted strength gain, % 35.152 ± 2.265 39.254 ± 3.841 67.104 ± 21.183
Values are means ± SE.  Arm mass-adjusted strength = (1 RM biceps + 1 RM triceps) / 
arm circumference.  Leg mass-adjusted strength = (1 RM hamstring curl + 1 RM leg 
extension) / thigh circumference.  P > 0.05 for GG and AG genotypes 
(analysis of covariance). * AA genotype N = 1. 
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Table 16 Muscle Phenotype Responses to RET by rs1418442 Genotype.  
 AA AG GG 
Lean muscle mass gain, % 2.098 ± 0.576 2.794 ± 0.420 2.240 ± 0.729 
Arm mass-adjusted strength gain, % 37.481 ± 3.984 38.875 ± 2.903 40.481 ± 5.040
Leg mass-adjusted strength gain, % 35.372 ± 3.815 37.693 ± 2.779 34.945 ± 4.826
Values are means ± SE.  Arm mass-adjusted strength = (1 RM biceps + 1 RM triceps) / 
arm circumference.  Leg mass-adjusted strength = (1 RM hamstring curl + 1 RM leg 
extension) / thigh circumference.  P > 0.05 for genotype (analysis of covariance). 
 
4.3 BETWEEN SNP INTERACTIONS - PERCENT CHANGE IN LEAN MUSCLE 
MASS 
There were no statistically significant differences observed between each individual SNP and 
percent change in lean muscle mass following RET.  However, the statistical model examining 
the interaction between two SNPs, rs2494735 (AKT1) and rs3001371 (AKT1) showed a 
statistically significant difference in percent change in lean muscle mass (P=0.036).  Therefore, a 
least significant difference post-hoc test was completed to show which genotypes were 
associated with percent changes in lean muscle mass following RET.  The covariates used in 
each statistical model were gender, age (<19.5 years or >19.5 years) and RET history (0 hours 
per week, 0.1-1.8 hours per week or >1.8 hours per week during the past year). Table 17 shows 
the significant interactions between various rs2494735 (AKT1) and rs3001371 (AKT1) 
genotypes.   
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Table 17  Percent Change In Lean Muscle Mass by rs2494735 and rs3001371Genotype 
 
Genotype N Mean Standard Error Significance 
AA/CC  
AG/CC 
41 
9 
2.565 1.143 0.027 
AA/CC  
GG/CT 
41 
3 
5.975 2.099 0.005 
AA/CC  
GG/TT 
41 
11 
2.788 1.054 0.009 
AG/CT  
GG/CT 
39 
3 
3.766 1.886 0.048 
AG/CT  
GGTT 
39 
11 
2.432 1.061 0.024 
AG/TT  
GG/TT 
11 
11 
2.655 1.332 0.049 
GG/CT  
GG/TT 
3 
11 
6.198 2.042 0.003 
Genotypes presented are interactions between various rs2494735 and rs3001371 genotypes.  
Values are marginal means ± SE.  Covariates are gender, age and strength training history. 
4.4 BETWEEN SNP INTERACTIONS - PERCENT CHANGE IN ARM MASS-
ADJUSTED STRENGTH 
Similar to the results for percent change in lean muscles mass, there were no significant 
differences between participant genotypes for each individual SNP and percent change in arm 
mass-adjusted strength following RET. Arm mass-adjusted strength was calculated as [1 RM 
biceps (kg) + 1 RM triceps (kg)/arm circumference (cm)].  Appendix F contains pre and post 
RET results for MERET participants by genotype for each component of the arm mass-adjusted 
strength calculation; 1 RM biceps, 1 RM triceps and arm circumference.  Two significant 
interactions did exist in the statistical models comparing rs1130214 (AKT1) with rs1124900 
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(AMPKα2) (P=0.042) and also rs1124900 (AMPKα2) with rs2796516 (AMPKα2) (P=0.009).  A 
least significant difference post-hoc test was used to examine the interactions between each 
individual genotype with percent change in arm mass-adjusted strength following RET.  Tables 
18 and 19 show the significant interactions between rs1130214 (AKT1) and rs1124900 
(AMPKα2) and rs1124900 (AMPKα2) and rs2796516 (AMPKα2), respectively, by genotype.   
Table 18 Percent Change in Arm Mass-Adjusted Strength by Genotype rs1130214 and rs1124900 
Genotype N Mean Standard Error Significance 
GT/GG  
GT/GT 
12 
25 
15.480 7.099 0.031 
Genotypes presented are interactions between various rs1130214 and rs1124900 genotypes.  
Arm mass-adjusted strength = (1 RM biceps + 1 RM triceps) / arm circumference. Values 
are marginal means ± SE.  Covariates are gender, age and strength training history. 
 
Table 19 Percent Change in Arm Mass-Adjusted Strength by Genotype rs1124900 and rs2796516 
Genotype N Mean Standard Error Significance 
TT/GG  
TT/AG 
15 
13 
22.841 8.110 0.006 
TT/GG 
GT/GG 
15 
40 
19.659 6.352 0.003 
GG/GG  
TT/AG 
28 
13 
13.931 7.147 0.054 
GG/GG  
GT/GG 
28 
40 
10.749 5.174 0.040 
Genotypes presented are interactions between various rs1124900 and rs2796516 genotypes.  
Arm mass-adjusted strength = (1 RM biceps + 1 RM triceps) / arm circumference.  Values 
are marginal means ± SE.  Covariates are gender, age and strength training history. 
4.5 BETWEEN SNP INTERACTIONS - PERCENT CHANGE IN LEG MASS-
ADJUSTED STRENGTH 
Leg mass-adjusted strength was calculated as [1 RM hamstring curl (kg) + 1 RM leg extension 
(kg)/thigh circumference (cm)].  Appendix G contains pre and post RET results for MERET 
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participants by genotype for each component of the leg mass-adjusted strength calculation; 1 RM 
hamstring curl, 1 RM leg extension and thigh circumference.  There were no significant 
differences between participant genotypes for each individual SNP and percent change in leg 
mass-adjusted strength following RET.  The statistical model comparing the interaction between 
rs2494735 (AKT1) and rs1130214 (AKT1) did, however, produce a significant association 
(P=0.036).  To further examine this result, a least significant difference post-hoc test was used to 
probe for differences in participant genotypes and percent change in leg mass-adjusted strength 
following RET.  Table 20 shows the significant interactions between rs2494735 (AKT1) and 
rs1130214 (AKT1) with percent change in leg mass-adjusted strength by participant genotype.  
Table 20 Percent Change in Leg Mass-Adjusted Strength by Genotype rs2494735 and rs1130214 
Genotype N Mean Standard Error Significance 
AA/GG  
GG/TT 
24 
5 
19.271 9.931 0.055 
AG/TT  
AG/GT 
5 
28 
19.519 9.769 0.048 
AG/TT  
GG/TT 
5 
5 
30.469 12.795 0.019 
GG/GG 
AA/GG 
3 
24 
27.844 12.451 0.027 
GG/GG  
AA/GT 
3 
14 
28.406 12.909 0.030 
GG/GG  
AA/TT 
3 
3 
41.053 16.619 0.015 
GG/GG  
AG/GG 
3 
25 
35.497 12.407 0.005 
GG/GG  
AG/GT 
3 
28 
36.165 12.347 0.004 
GG/GG  
GG/GT 
3 
8 
35.226 13.680 0.011 
GG/GG  
GG/TT 
3 
5 
47.115 14.876 0.002 
Genotypes presented are interactions between various rs2494735 and rs1130214 genotypes.  
Leg mass-adjusted strength = (1 RM hamstring curl + 1 RM leg extension) / thigh 
circumference. Values are marginal means ± SE.  Covariates are gender, age and strength 
training history. 
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5.0  DISCUSSION 
The mammalian target of rapamycin (mTOR) signaling pathway has been shown to be an 
important mediator of protein synthesis and skeletal muscle hypertrophy in adult animals (11).    
Previous investigations using the MERET cohort have shown that gender, age and RET history 
are significant predictors of percent gains in lean muscle mass, muscle strength, and muscle 
quality following standardized RET (32, 33).  The aim of this investigation was to examine if 
specific SNPs of two genes that are an integral part of the mTOR signaling pathway could help 
explain some of the variability in skeletal muscle response to RET.  Therefore, we examined four 
SNPs from the AKT1 gene and 3 SNPs from the AMPKα2 gene for possible associations with 
percent changes in lean muscle mass, arm mass-adjusted strength, and leg mass-adjusted 
strength, following a standardized 10-week RET program.  Although none of the SNPs were 
independently associated with significant percent changes in lean muscle mass, arm mass-
adjusted strength, or leg mass-adjusted strength following RET, several interactions between 
SNPs were found which could prove to be interesting candidates for future investigations. 
5.1 PERCENT CHANGE IN LEAN MUSCLE MASS 
It is reasonable to assume, given the complexity of the mTOR signaling pathway, that any 
variability in the normal cascade of reactions this pathway undergoes in order to trigger protein 
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synthesis could help explain some of the variability in skeletal muscle response to RET.  
Previous research has shown that AKT1 is involved in the intracellular signaling mechanisms 
controlling protein synthesis, a vital precursor of muscle growth (11, 13, 21).  However, the 
current literature is dominated with studies that show a significant increase in AKT1 expression 
following RET (11, 19, 20), and lacking on studies examining which specific AKT1 SNPs may 
be associated with the variability in skeletal muscle response to RET.  The significant interaction 
effect observed in percent change in lean muscle mass in this investigation occurred between two 
SNPs from the AKT1 gene, rs2794735 and rs3001371.  Given AKT1’s reputation as a controller 
of protein synthesis and protein degradation, any polymorphisms in this gene may possibly play 
a role in an individual’s rate of protein synthesis and or protein degradation following RET (17).  
An individual’s ability to synthesize protein could have a direct effect on their ability to build 
lean muscle mass following RET.   For example, a previous investigation showed AKT1 
expression increased significantly in association with protein synthesis 1-2 hours post-RET (19).  
It is possible that the interaction observed between rs2794735 and rs3001371 could influence the 
rate of AKT1 expression post-RET.  This, in-turn, could affect protein synthesis and 
subsequently the ability to build lean muscle mass post-RET.   
5.2 PERCENT CHANGE IN ARM MASS-ADJUSTED STRENGTH 
A secondary analysis performed in this investigation was to examine any associations between 
the selected SNPs of the AKT1 and AMPKα2 genes and percent changes in arm mass-adjusted 
strength following RET.  None of the seven SNPs examined were independently associated with 
significant percent changes in arm mass-adjusted strength following RET.  However, there were 
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two significant interactions between SNPs that were associated with percent change in arm mass-
adjusted strength following RET.  The first was a significant gene-gene interaction between 
rs1130214 (AKT1) and rs1124900 (AMPKα2).  In contrast to AKT1, which acts on the mTOR 
signaling pathway to increase protein synthesis, the goal of the AMPK gene is to keep the cell in 
homeostasis.  AMPK is up-regulated during times of increased protein synthesis, in an effort to 
return the cell to homeostasis, by signaling the mTOR pathway to repress protein synthesis.  The 
appearance of an adversarial relationship between AKT1 and AMPK, makes the significant 
interaction observed in percent change in arm mass-adjusted strength following RET between 
rs1130214 (AKT1) and rs1124900 (AMPKα2) an interesting one (27).  While much more work 
needs to be done, a possible explanation for this finding is that this particular rs1130214 (AKT1) 
and rs1124900 (AMPKα2) genotype combination (GT/GG GT/GT) could allow AKT1 signaling 
to influence the mTOR pathway more strongly than AMPK, resulting in an increase in protein 
synthesis, as opposed to a repression of protein synthesis. 
The second significant interaction observed in percent change in arm mass-adjusted 
strength following RET was between rs1124900 and rs2796516, two SNPs from the AMPKα2 
gene.  This finding was of interest because under normal conditions, AMPK works to suppress 
energy-consuming processes, like protein synthesis, while enhancing energy producing 
processes.  The finding that some of the genotypes between these two SNPs interacted to 
significantly increase the percent change in arm mass-adjusted-strength following RET could be 
explained by the possibility that these genotypes may alter the normal function of this gene.  If 
these genotype interactions compromise AMPK’s ability to properly signal the mTOR pathway 
to repress protein synthesis under conditions of increased stress, such as RET, then perhaps 
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protein synthesis is allowed to continue for a longer period of time, resulting in increased cell 
growth for individuals possessing these particular genotype combinations.   
5.3 PERCENT CHANGE IN LEG MASS-ADJUSTED STRENGTH 
The interaction between rs2494735 and rs1130214, both AKT1 SNPs, was significantly 
associated with an increase in percent change in leg mass-adjusted strength following RET.  
These findings are similar to those observed for percent change in lean muscle mass following 
RET, in that both sets of SNPs are from the AKT1 gene.  Individuals who possess particular 
AKT1 genotypes, like those in Tables 10 and 13, may be more efficient at synthesizing protein 
following RET as opposed to those individuals with other AKT1 genotypes.  Additionally, these 
AKT1 genotypes may affect the rate of AKT1 expression following RET, which could also 
affect the rate of protein synthesis.  This may explain why some of the MERET participants had 
more favorable muscle mass and muscle strength responses following RET than other MERET 
participants.   
The significant between SNP interactions for percent change in lean muscle mass, 
percent change in arm mass-adjusted strength, and percent change in leg mass-adjusted strength 
following RET noted in this report should be viewed as preliminary due to the inequality in the 
number of participants being compared.  In many cases there were large differences in the 
number of participants with a particular genotype that were being compared with participants 
with another genotype (Tables 17-20). This was due to the many genotype combinations that 
exist when examining participant data for interactions between two different SNPs.  
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5.4 LIMITATIONS 
There are several limitations associated with this investigation.  First, the number of participants 
in the between SNP interaction analyses is relatively small.  A larger number of participants is 
needed in order to achieve sufficient statistical power to examine the AKT1 and AMPKα2 
between SNP interactions in relation to percent change in lean muscle mass, arm mass-adjusted 
strength, and leg mass-adjusted strength following RET.  Second, there are currently more 
accurate ways to examine changes in muscle mass following RET.  Dual-energy x-ray 
absorptiometry (DEXA) is one method that would allow for a more accurate quantification of 
muscle mass gains following RET.  Third, muscle biopsies would allow for the analysis of 
AKT1 and AMPKα2 gene expression.  An analysis could then be performed to examine any 
interactions between AKT1 and AMPKα2 SNPs and changes in the expression of these two 
genes pre and post-RET. 
5.5 CONCLUSION 
In conclusion, none of the AKT1 and AMPKα2 SNPs examined in this investigation were 
independently associated with percent change in lean muscle mass, arm mass-adjusted strength, 
or leg mass-adjusted strength following RET.  However, there is preliminary evidence of 
associations to lean muscle mass and muscle strength responses of the MERET cohort to RET 
based on interactions between the SNPs of the AKT1 and AMPKα2 genes examined in this 
report.  The individual response to standardized RET varies greatly from person to person.  As 
future research begins to unravel the complexity of the mTOR signaling pathway and the specific 
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role its genes play in the development of muscle hypertrophy following RET new light will be 
shed on the inter-individual response to standardized RET.      
5.6 RECCOMMENDATIONS FOR FUTURE RESEARCH       
While additional studies with larger sample sizes are needed to confirm any associations between 
the SNPs examined in this investigation and variations in percent changes in lean muscle mass, 
and muscle strength following RET, the information presented here provides a solid base for 
future research to expand upon.  Future research involving the AKT1 and AMPKα2 genes could 
take the approach of focusing more specifically on the above mentioned genotypes to further 
examine any associations to the variability of skeletal muscle response to RET.  Future studies 
could also examine the potential interactions between the AKT1 and AMPKα2 genes with other 
genes of the mTOR signaling pathway in relation to the individual variability of muscle response 
to RET.  Though complex, the mTOR signaling pathway contains numerous genes that could 
prove to be excellent candidates for studies examining the variability of muscle response to RET.  
As new SNPs from the genes of the mTOR pathway are discovered, particularly those that result 
in amino acid changes, future studies should examine the possible role they may play in the 
individual response to RET.  Given the sheer size and scope of the mTOR signaling pathway, 
combined with its biological outcome of protein translation and cell growth, there is near 
unlimited potential for future investigations to examine this pathway’s relationship to muscle 
hypertrophy and strength gains following RET.   
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APPENDIX A 
MEDICAL HISTORY 
1. Name    _____________________________________ 
 
2. Date of Birth  /  / 
                                     month / day / year 
 
3. Gender  Male  Female 
 
        --------------------------------------------------------------- 
                               Medical History 
 
4. Are you presently taking any prescribed or over the counter medication? 
(including birth control pills, insulin, allergy shots or pills, asthma 
inhalers, vitamin or mineral supplements including iron, 
anti-inflammatories including aspirin) 
 
     Yes  List Name of Medication Dose Frequency of Use 
 
1.______________________________________________________________________________ 
2.______________________________________________________________________________ 
3.______________________________________________________________________________ 
4.______________________________________________________________________________ 
 
 NO 
 
5. Do you have an allergy to any: 
              Specify Allergy: 
     a. drug or medicine (over the counter or 
      prescribed)       Yes No  
     b. foods        Yes No  
     c. insects or animals       Yes No  
     d. plants, grasses, pollen, dust or other  
      environmental factors      Yes No  
  e. other 
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6. Has a doctor ever told you that you have had any of the following 
medical problems?(if you don't know, mark 'No') 
 
a. birth defect   Yes No   t. stomach or intestinal ulcer  Yes No  
b. frequent urinary infections  Yes No   u. sickle cell anemia   Yes No 
c. kidney injury   Yes No   v. other anemia     
d. other kidney disease  Yes No   w. abnormal bleeding or clotting  
e. blood clot or embolism Yes No           disorder   Yes No  
f. diabetes   Yes No   y. leukemia or other blood    Yes No  
g. hernia    Yes No      disorder    Yes No  
h. jaundice   Yes No    
i. epilepsy   Yes No   
j. tumor, growth, cyst,      
     cancer     Yes No    
k. over-active thyroid   Yes No    
l. under-active thyroid    Yes No        
m. arthritis             Yes No    
n. Marfan syndrome     Yes No    
o. oral herpes (cold sores)  Yes No    
p. genital herpes          Yes No    
q. injury to liver or  Yes No    
r. spleen                    Yes No    
s. hepatitis    Yes No  
 
7. Have you ever had surgery to the following: 
 
        Date         If yes, give reason for 
                                           (month/year) surgery: 
     eyes             Yes No  / 
     ears/nose/throat     Yes No  / 
     heart     Yes No  / 
     lungs     Yes No  / 
     stomach or bowels   Yes No  / 
     kidneys     Yes No  / 
     liver/spleen     Yes No / 
     bone      Yes No / 
     muscle/ligament/tendon  Yes No / 
     joint     Yes No  / 
     other (please specify)   Yes No  / 
 
8. During or after exercise, have you ever: 
  
     been dizzy or light- headed?      Yes No  
     passed out (fainted)?       Yes No  
     had chest pain, discomfort or tightness?     Yes No  
     found it more difficult to breath than usual?    Yes No  
     had problems with coughing?      Yes No  
 
9. Have you ever been told that you have a heart murmur?   Yes No 
 
10. Have you ever had racing of your heart, irregular or skipped 
beats?         Yes No 
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11. Have you ever been told by a doctor that you have had: 
      high blood pressure?       Yes No  
     pericarditis, myocarditis, endocarditis (infections of the 
     heart)?        Yes No  
     rheumatic fever?       Yes No  
     other heart or vascular problems? (please specify)    Yes No  
 
12. Have you ever had any medical tests for your heart (i.e. EKG, 
echocardiogram)? 
 
     Yes (if so, specify test and reason below) 
     Test Reason 
 
     No 
 
13. Have you ever had:         
     tuberculosis?        Yes No  
     asthma?        Yes No  
     wheezing that starts during or just after exercise?    Yes No  
     pneumothorax (collapsed lung)?      Yes No  
 
14. Have you ever had a concussion (injury to the head) with or without 
loss of consciousness? 
 
     Yes  
     How many times? 1x 2x 3x 4x 5x >5x 
 
     No 
 
15. Have you ever been knocked unconscious? 
 
     Yes  
     How many times? 1x 2x 3x 4x 5x >5x 
      
     What is the longest time that you have been unconscious due to a head 
     injury? 
     A few seconds Up to 5 minutes 6-15 minutes >15 minutes 
 
     No 
 
16. Have you ever had any long term problems due to a head injury (e.g. 
memory loss, headaches)? 
 
     Yes No 
 
17. Have you ever had numbness, tingling, or weakness in your: 
 
  
     shoulders/arms/hands?  Yes No  
     buttocks?   Yes No  
     legs/feet?   Yes No  
 
18. Have you ever had a seizure? Yes No 
 
19. Do you experience migraine headaches? Yes No 
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        --------------------------------------------------------------- 
                     WOMEN ONLY, MEN SKIP TO QUESTION #23 
 
20. When was your most recent menstrual period? 
 
 
     <1 month ago  1-3 months ago 4-6 months ago  >6 months ago 
 
21. In the past 12 months: 
  
     have you had trouble with heavy menstrual bleeding?  Yes No  
     have you had bleeding between periods?    Yes No  
     have you had menstrual cramps or pain which affected your 
     school or athletic performance?     Yes No  
     what was the longest time between periods? 
  <1 month  1-3mo  4-6mo  >6mo 
     on average how long has each period lasted? 
  1-5 days  6-10d  11-15d  >15d 
 
22. Are you presently taking any female hormones (estrogen, progesterone, 
birth control pills) for the purpose of regulating your periods? Yes No 
 
--------------------------------------------------------------- 
                             Orthopaedic History 
 
23. In the past 12 months have you seen a physician, athletic trainer or 
other health care professional for a new or ongoing injury? 
 
     Yes (if so, please complete a list below) 
     Specify injury(s): Has this injury healed completely? 
                        Yes No 
                        Yes No 
                        Yes No 
                        Yes No 
                        Yes No 
 
24. Do you presently use for practice or competition: 
     a. brace, splint, or sleeve? Yes No  
     b. orthotics (shoe inserts)? Yes No  
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    QUESTIONS 25-36 
 
    Have you ever had or do you currently have an injury or problem of the 
    following: 
    (if you don't know, indicate 'No') 
 
                                Place an                                                                  Place an 
                                 "x" if                                                                   "x" if 
                               condition                                                                 condition 
                              exists at                                                               exists at 
                          Yes No  present                    Yes No  present 
25. Neck: 
    disc disease                           facet disorder 
    traumatic fracture                      surgery 
    stress fracture                        other 
    whiplash                                specify: 
 
26. Spine / Back: 
    cogenital deformity 
    or birth defect     disc disease 
    facet disorder     sacroiliac disorder 
    traumatic fracture   ciatica 
    stress fracture     scoliosis 
    back pain     surgery 
    back stiffness                   
    spondyloysis                            other 
    spondylolisthesis                       specify:  
 
27. Shoulder / Clavicle: 
    traumatic fracture                      subluxation 
    bursitis                                dislocation 
    acromioclavicular 
    (AC) separation                         surgery 
    rotator cuff 
    tendonitis/                            other 
    impingement     specify: 
    instability  
 
.28. Upper arm / forearm: 
    traumatic fracture                      surgery 
    muscle injury                          other 
    tendon injury                          specify: 
 
29. Elbow: 
    traumatic fracture                      dislocation 
    ligament injury                         surgery 
    tennis (golfer's) 
    elbow                                   other 
    bursitis                                specify: 
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30. Hand, Wrist, Fingers: 
    traumatic fracture                      dislocation 
    stress fracture                        surgery 
    ligament injury                         other 
     tendon injury or tendonitis                        specify: 
 
31. Pelvis / Hip: 
    traumatic fracture                                   tendonitis 
    stress fracture                         contusion/hip 
     pointers 
    groin strain                            surgery 
    dislocation                            other 
    bursitis                                            specify: 
 
32. Thigh: 
 
    traumatic fracture                     quadriceps 
          strain/injury 
    stress fracture                         severe contusion 
    tendonitis                             surgery 
    bursitis                                other 
    hamstring     specify: 
    strain/injury  
 
33. Knee: 
    meniscal injury                         locking 
    PCL tear                                dislocation of 
                                             knee or patella  
    ACL tear     (knee cap) 
    iliotibial band 
    syndrome                                swelling 
    collateral ligament 
    injury                                  unexplained pain 
    tendonitis                              meniscal surgery 
    bursitis                                ACL surgery 
    pain around knee 
    cap,                                    other injury or 
    (patello-femoral                        surgery 
    pain)      pecify: 
    sensation of 
    catching, 
    instability, giving  
    away 
 
34. Lower Leg: 
    traumatic fracture                      shin splints 
    stress fracture                                     surgery 
    muscle strain                          other 
    compartment     specify: 
    syndrome  
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35. Ankle: 
 
    traumatic fracture                     bone chip in joint 
    stress fracture                        dislocation 
    sprain                                 surgery 
    tendonitis                             other 
    bursitis   specify: 
    instability 
 
36. Foot / Toes: 
 
    traumatic fracture                    flat arches of feet 
    stress fracture                       dislocation 
    sprain                                 surgery 
    tendonitis or 
    tendon injury                          other 
    bone spur   specify: 
    plantar fasciitis 
 
37. In the past 10 years, have you been treated for a serious injury(s) not 
    mentioned above? 
 
     Yes (if so, please specify below) 
     Specify injury(s): Date (month/year): 
                        / 
                        / 
                        / 
 
     No 
 
38. Have you ever had a cortisone injection into a tendon, bursa, or joint 
    for an injury or pain? 
 
     Yes (if so, please specify below) 
     Specify injury(s): Date (month/year): 
                        / 
                        / 
 
     No 
 
39. Please indicate your ethnic origin (place an 'x' in all that apply) 
 
 
     Native American / Alaska native   Hispanic/Latino/Chicano 
     Asian                                White (non-Hispanic) 
     Pacific Islander                   Other, specify: 
     Black/African American            Don't know 
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        --------------------------------------------------------------- 
                                Health Habits 
 
40. Have you ever been diagnosed as having an eating disorder? 
 
     Yes No 
 
41. Have you ever tried to control your weight with: 
 
 
                  Yes No 
     fasting? 
     vomiting? 
     laxatives? 
     diuretics? 
     diet pills? 
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APPENDIX B 
MODIFIABLE ACTIVITY QUESTIONNAIRE 
Please identify all activities you have done more than 10 times in the past year. 
 
Activity J 
A 
N 
F 
E 
B 
M
A 
R 
 
A 
P 
R 
M
A 
Y 
J 
U 
N 
J 
U
L 
A
U
G
S 
E
P
O 
C 
T 
N 
O 
V 
D 
E 
C 
Average 
# of 
times 
each 
month 
Average 
# of 
minutes 
each 
time 
Jogging (outdoor, treadmill)               
Swimming (laps, snorkeling)               
Bicycling (indoor, outdoor)               
Softball/Baseball               
Volleyball               
Bowling               
Basketball               
Skating (roller, ice, blading)               
Martial Arts (karate, judo)               
Tai Chi 
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 Activity 
J 
A 
N 
F 
E 
B 
M
A 
R 
 
A 
P 
R 
M
A 
Y 
J 
U 
N 
J 
U
L 
A
U
G
S 
E
P
O 
C 
T 
N 
O 
V 
D 
E 
C 
Average 
# of 
times 
each 
month 
Average 
# of 
minutes 
each 
time 
Calisthenics/Toning 
exercises 
              
Wood Chopping               
Elliptical Trainer               
Football/Soccer               
Racquetball/Handball/Squash               
Horseback riding               
Hunting               
Fishing               
Aerobic Dance/Step Aerobic               
Water Aerobics               
Dancing (Square,Line,Ballrm)               
Gardening or Yardwork               
Badminton               
Strength/Weight training               
Rock climbing               
Scuba Diving               
Stair Master/Stair Climbing               
Fencing               
Hiking               
Tennis               
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Activity J 
A 
N 
F 
E 
B 
M
A 
R 
 
A 
P 
R 
M
A 
Y 
J 
U 
N 
J 
U
L 
A
U
G
S 
E
P
O 
C 
T 
N 
O 
V 
D 
E 
C 
Average 
# of 
times 
each 
month 
Average 
# of 
minutes 
each 
time 
Golf               
Canoeing/Rowing/Kayaking               
Water skiing               
Jumping rope               
Snow skiing (X-
country/Nordic trk) (downhill) 
              
Snow shoeing               
Yoga               
Other               
Walking for exercise 
(outdoor, indoor at mall or 
fitness center, treadmill 
              
 
2. In general, how many HOURS per DAY do you usually spend watching television?   __________ hrs 
 
3. Over this past year, have you spent more than one week confined 
to a bed or chair as a result of an injury, illness or surgery                          Yes________   No_______ 
     If yes, how many weeks over this past year were you confined to 
     a bed or chair?                                                                                                  ____________ weeks 
 
4. Do you have difficulty doing any of the following activities? 
a.  getting in or out of a bed or chair?                                                   Yes________          No________ 
b.  walking across a small room without resting?                                 Yes________          No________ 
c.  walking for 10 minutes without resting?                                           Yes________          No________ 
 
5. Did you ever compete in an individual or team sport (not including any time spent in sports performed 
during school physical education classes)? 
     If yes, how many total years did you participate in competitive sports?                ________years 
 
6. Have you had a job for more than one month over this past year, from last ____________ to this 
____________? 
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APPENDIX C 
INFORMED CONSENT 
     Approved: 01/26/2000 
       Institutional Review Board  
                                                                 University of Pittsburgh 
                                                                           IRB Number: 991278  
                  Renewal Date: 1/11/2001 
 
 CONSENT TO ACT AS A SUBJECT IN A RESEARCH STUDY 
 
 
TITLE: Genetic Predisposition to Myosthenic and Sarcopoietic Responses to   
Resistance Exercise. 
 
Principal Investigator:  Steven E. Riechman, Ph.D. 
    A 300 Crabtree Hall 
    Department of Human Genetics 
    Graduate School of Public Health  
    University of Pittsburgh 
    Pittsburgh, PA  15261 
    (412) 383-8733 
Co-investigators:   
 
Robert E. Ferrell, Ph.D.      Stephen M. Roth, Ph.D. 
Department of Human Genetics   Department of Human Genetics 
Graduate School of Public Health    Graduate School of Public Health  
University of Pittsburgh    University of Pittsburgh 
 Pittsburgh, PA  15261    Pittsburgh, PA  15261 
(412) 624-3018     (412) 624-4697 
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David E. Kelley, M.D.      Bret Goodpaster, Ph.D. 
Division of Endocrinology    Division of Endocrinology 
School of Medicine, 412-692-2437   School of Medicine, 412-692-2158 
University of Pittsburgh    University of Pittsburgh 
Pittsburgh, PA  15261     Pittsburgh, PA  15261 
 
Robert J. Robertson, Ph.D.     Ben Hurley, Ph.D. 
Health Physical Recreation and Education Dept  Department of Kinesiology 
Center for Exercise and Health-Fitness Research  University of Maryland 
University of Pittsburgh, 412-648-8251  College Park, MD  20742 
113 Trees Hall     (301) 405-2486 
Pittsburgh, PA  15261     
 
Source of Support: Developmental and Feasibility Multipurpose Arthritis and   
Musculoskeletal Disease Center Grant MAMDC 
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DESCRIPTION: 
 You are being asked to participate as a volunteer in a research investigation. In this 
research investigation, you will be on a supervised ten-week strength-training program which 
requires your participation for one hour, three days per week.  You are being asked to participate 
in this study because you are a healthy male or female between the ages of 18-30 years without 
any medical conditions.  In this study, the researchers are trying to determine if genetic markers 
are related to the ability to increase muscle size and strength in response to strength training 
exercise.  If you are selected for the training, a DNA sample will be collected and analyzed for 
common genetic variations thought to contribute to variations in muscle strength and size 
development.  A portion of the sample will be stored for future analyses if new genes involved in 
muscle development are discovered.  All samples will be destroyed after five years.  If you agree 
to participate in this research project, use of your donated DNA sample will be under the control 
of the principal investigator of this research project.  You will not be informed of your genetic 
results because the genetic data cannot yet be interpreted or applied in a clinically relevant or 
meaningful manner.   
 
 After consent to participate is obtained, you will be asked to spend ten minutes filling 
out a medical history questionnaire. From the eligible subjects, forty subjects will be randomly 
selected to participate in the weight training program.  If you are not selected you are still 
eligible to participate in the future. An equal number of males and females will be selected. 
Approximately 125 subjects are expected to enter this study.  40 subjects will be selected each 
semester.  Physical measurements are needed for this study to determine the changes that may 
occur during the strength training program, and your blood will be drawn and tested three times 
before you begin and after you have completed the ten week training program (six times total).  
The DNA for this study will be collected from these blood samples. 
 
If you agree to participate in this research study, you will undergo the following: 
 
1. Under supervision, you will have three days of familiarization with the strength equipment in 
the Trees Hall weight room at the University of Pittsburgh. 
2. Next, you will have a sixty-minute testing session in Trees Hall.  Your one repetition 
maximum (1RM) will be determined for each of the following twelve exercises: leg press, 
chest press, seated row, lat pull downs, leg extensions, triceps extension, arm curl, shoulder 
press, leg curl, low back, abdominal crunch and incline press.  To determine your 1RM, you 
will be asked to select the maximum weight that you feel you can lift one (1) time. You will 
be asked to lift 50% of that weight three times to warm up. After sixty seconds of rest, you 
will make an attempt to lift 90% of the estimated maximal resistance one time.  A refined 
estimation of maximal strength will then be attempted following 60 seconds of rest.  
Thereafter, the increases in resistance will be adjusted so as to minimize the total number of 
trials required before the true 1 RM value is obtained., i.e. the highest resistance at which one 
repetition can be successfully completed. 
3. In order to measure the amount of lean and fat tissue in your body, you will have a scan 
performed which is called a "DEXA" (dual-energy x-ray absorptiometry) scan.  This scan is 
performed similar to an x-ray study and you will lie on an examination table in a room with 
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the DEXA scanner for approximately 30 minutes.  There are no contrast injections or blood 
samples, and the test is painless except for any discomfort you may experience because of 
lying on my back on the firm examination table. This will be performed before and after the 
strength training. 
4. Baseline assessments of the following will be obtained at the Human Energy Research 
Laboratory (HERL): height, weight, body fat measurement by underwater weighing, bicycle 
test for assessment of sprinting capacity, and size measurements of shoulders, chest, arms, 
forearm, thigh, waist, calves and hips, skinfold measurements of chest, abdominal, arms, hip, 
thigh, calf, back.  Blood samples (2-3 tablespoonful) will be collected in the morning before 
you begin your first workout after at least 6 hours of fasting and tested for: lactate (exercise 
breakdown product of blood sugar), glucose (blood sugar), testosterone (male hormone), 
insulin like growth factor I (IGF I-muscle building hormone), IGF-B3 (insulin like growth 
factor binding protein-transports IGF-I), and creatine kinase (marker of muscle breakdown). 
These blood measurements are related to exercise and muscle activity and development.  
Another 2-3 tablespoonful of blood will be drawn after your first training session.  A third 
blood sample of 2 teaspoonfuls will be taken 24 hours after the first workout for the 
measurement of creatine kinase. Fasting is not required for this sample. During the 
underwater weighing procedure you will be asked to enter a warm water tank in your bathing 
suit. You will then be asked to blow out all your air while underwater and hold it for about 
two seconds.  This procedure will be repeated about five times to insure an accurate 
measurement.  You may take a break between attempts for as long as you like.  The bicycle 
test asks that you pedal as hard as you can for thirty seconds. 
5. Strength training will be done for one hour at a time, three days per week for ten weeks (30 
one-hour sessions total) with at least one day of rest in between sessions. 
6. Approximately 2-3 tablespoons of blood will be drawn both before and after your last 
workout of the 10-week program.  Testing on the blood sample will be the same as the blood 
test prior to the program lactate, glucose, testosterone, Insulin like growth factor I (IGF I), 
IGF-B3 (insulin like growth factor binding protein), creatine kinase, blood glucose, total 
cholesterol, triglycerides, total HDL, and HDL2).   Physical measurements (height, weight, 
body fat measurement by hydrostatic (underwater) skinfold measurements of chest, 
abdominal, triceps, hip, thigh, calf, subscapula, weighing, bicycle ergometer for assessment 
of anaerobic capacity, and circumference measurements shoulders, chest, arms, forearm, 
thigh, waist, calves and hips) will also be performed again. 
           
Your participation in this study will require you to spend approximately one hour for the 
three initial visits, one hour for the 1 RM and physical measurements and one hour for each of 
the three sessions per week for the ten week weight training program in Trees Hall.  One of the 
investigators will be present to assist if necessary.  A spotter will be present if you cannot 
perform the assigned number of repetitions in each set.  If you fail to complete a repetition, the 
spotter will assist you in that lift. You will be instructed to exhale during the contraction phase of 
each repetition for every exercise. 
 
The tests are being conducted in a research laboratory that is not certified for diagnostic testing.  
Therefore the results of these tests will not be given to you and will not become part of your medical 
record.  In addition to the genes named above, research in human genetics and physiology is likely 
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to identify new genes or new pathways involving known genes that may influence muscle function.  
These new genes may also be tested without specifically notifying you.  Your DNA will not be used 
for studies other than muscle function without contacting you to obtain your consent.  
          
RISKS AND BENEFITS:
 The risks associated with weight training exercise, bicycle sprint test and underwater 
weighing are low.  Weight training, the bicycle sprint test and underwater weighing may be 
harmful in individuals with high blood pressure, abnormal heart rhythms and musculoskeletal 
injuries. You may feel light-headed or nauseous after the bicycle test.  This is a common 
response and occurs in not more than 25 out of 100 people. You will be asked to continue to 
cycle to reduce lightheadedness and nausea.  You may feel a strong desire to breathe during the 
underwater test. To minimize these risks, you will complete a medical history questionnaire and 
an exercise physiologist will conduct these tests. Because you will be required to lift heavy 
weight and perform unfamiliar exercises, you may experience some muscle soreness or injury to 
muscle, tendon or ligaments. Initially it is likely you will be sore for 3-5 days (more than 25 out 
100 people).  The soreness associated with each workout should diminish within two weeks of 
training.  You should alert the investigative team if soreness, pain or other unusual symptoms 
persist or become intensified during the training.  The investigative team will ask you at each 
training session about these symptoms. .  You will be continually monitored and corrected with 
respect to lifting technique. You will also be asked to warm up and cool down to minimize the 
risk of injury and soreness.  Having blood taken may cause pain, bruising, infection and fainting. 
These effects are common and occur in up to 25 out of 100 people. A person trained to take 
blood will be used to decrease these risks. You will also be asked to complete a medical history 
to identify conditions that might be worsened by this training program. If you have one of these 
conditions, you will not be asked to participate.    
 This study will provide you with information about your muscular strength, 
endurance, and body fat.  You will be taught proper weight lifting techniques. Strength training 
can contribute to healthy lifestyle and reduction of risk for many diseases. Participation in this 
study may contribute to the advancement of scientific knowledge concerning genetic variation 
and strength training. 
Participation in this research study involves a small amount of radiation exposure from 
the DEXA scans (1 mrem, a unit of radiation exposure to the whole body for each scan). If you 
participate in both the pre-weight training and post-weight training scans your exposure to 
radiation will be double  (2 mrems). For comparison, radiation workers are permitted by federal 
regulation, a maximum annual whole body radiation exposure of 5000 mrems. There is no 
known minimum level of radiation exposure that is recognized as being totally free of the risk of 
causing genetic defects (cellular abnormalities) or cancer.  However, the risk associated with the 
amount of radiation exposure that you will receive from this procedure is considered to be low 
and comparable to other everyday risks. If you are a woman of childbearing age you will have a 
urine pregnancy test performed 24 hours prior to the initial and, if applicable, repeat study and if 
positive, you will be excluded from the study. 
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NEW INFORMATION 
 You have been informed previously that you will not be informed of the genetic 
testing or other laboratory testing results.  You or your representative will be promptly notified if 
any other information about this research study develops during the course of the study which 
may cause you to change your mind about continuing to participate.  
 
 
COSTS AND PAYMENTS:
 There will be no charge to you for the participation in this study.  You will not 
receive payment for your participation in this study.  Your genetic material may lead, in the 
future, to new inventions or products.  If the research investigators are able to develop new 
products from the use of your genetic material, there are currently no plans to share with you 
monies that may result from such products. 
 
 
COMPENSATION FOR ILLNESS AND INJURY:
 University of Pittsburgh investigators and their associates who provide services at the 
UPMC Health System (UPMC HS) recognize the importance of your voluntary participation to 
their research studies.  These individuals and their staffs will make reasonable efforts to 
minimize, control, and treat any injuries that may arise as a result of this research. 
 If you believe that you are injured as the result of the research procedures being 
performed, please contact immediately the Principal Investigator listed on the cover sheet of this 
form or the University of Pittsburgh Institutional Review Board (412)-578-3424.  Emergency 
medical treatment for injured solely and directly related to your participation in this research will 
be provided to you by hospitals of the UPMC HS.  It is possible that the UPMC HS may bill 
your insurance provider for the costs of this emergency treatment, but none of these costs will be 
billed directly to you.  If your research-related injury requires medical care beyond this 
emergency treatment, you will be responsible for the costs of this follow up care unless 
otherwise specified below.  You will not receive monetary payment for, or associated with, any 
injury that you suffer in relation to this research. 
CONFIDENTIALITY:
 All records pertaining to your involvement in this study will be stored in a locked file 
cabinet at the Human Genetics Department in Parren Hall. Your identity on these case records 
will be indicated by a case number. This information will only be accessible to the investigators 
and their research study staff listed on the first page of this document. A code number will 
indicate your identity on tissue samples and the DNA. 
 You understand that any information about you or your participation will be handled 
in a confidential (private) manner consistent with other research records. You will not be 
identified in any publication of research results. However, in unusual cases, your research 
records may be inspected by appropriate government agencies or be released in response to an 
order from a court of law.  At the completion of the study, your research records will be kept 
under lock and key by the primary investigator for a period of five years at which time they will 
be destroyed. 
     
 
 69 
RIGHT TO WITHDRAW
 You understand that you do not have to take part in this study and, should you change 
your mind, that you can withdraw from the study at any time. Your status with the University 
and your other care and benefits (i.e. use of the weight room in Trees hall) will be the same 
whether you participate in this research study or not. You also understand that you may be 
removed from the research study by the investigators if you do not follow the instructions of the 
investigators. If you withdrawal or are removed from the study you will be given participation 
credit for each exercise session completed but not for testing sessions. All other class 
responsibilities will continue to be your responsibility. Your grade in class will not be influenced 
by your decision to participate nor by your decision to withdrawal.  You retain the right to have 
your genetic material destroyed.  
************************************************************************
************ 
VOLUNTARY CONSENT: 
 
 All of the above has been explained to me and all of my questions have been 
answered. I understand that any future questions I have about this research will be answered by 
the investigator(s) listed on the first page of this consent document at the telephone numbers 
given.  Any questions have about my rights as a research subject will be answered by the Human 
Subjects Protection Advocate of the IRB Office, University of Pittsburgh (412-578-8570). By 
signing this form, I agree to participate in the research study. 
 
 
_________________________                                      __________________________ 
Subject’s Signature                                                         Date 
 
_________________________                                      __________________________ 
Witness Signature                                                          Date 
 
 INVESTIGATOR’S CERTIFICATION: 
 
 I certify that the nature and purpose, the potential benefits, and possible risks 
associated with participation in the research study have been explained to the above individual 
and that any questions about the information have been answered. 
 
 
_________________________                                      __________________________ 
Investigator’s Signature                                                  Date 
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APPENDIX D 
MERET DATA COLLECTION SHEET 
Name: _________________________________       
      Date: __ __/ __ __/ __ __  
Test:             Pretest  Posttest Age: __ __  
Gender: Male  Female RBP: __ __ __/ __ __ __  
Race: Afr. Am.    Caucn.      RHR:__ __ __  
 Oriental     Hisp.     Oth. 
   
    
Anthropometrics    
     
Underwater weighing  Skinfolds (right side)  
Height (cm): 
__ __ 
__.__ tricep (mm) 
__ __.__/__ 
__.__ 
Height (in): __ __.__ 
Subscap 
(mm) 
__ __.__/__ 
__.__ 
Weight (kg): 
__ __ 
__.__ 
Suprailliac 
(mm) 
__ __.__/__ 
__.__ 
Weight (lb): 
__ __ 
__.__ calf (mm) 
__ __.__/__ 
__.__ 
RVpred: 
__.__ 
__ thigh (mm) 
__ __.__/__ 
__.__ 
WTUW (kg): 
__.__ 
__ Abdom (mm) 
__ __.__/__ 
__.__ 
% Fat: 
__ 
__.__ Chest (mm) 
__ __.__/__ 
__.__ 
water temp 
__ __ . 
__ Bone Widths (right)  
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__ 
__.__ Fat mass (lb): humerus (cm) 
__ __.__/__ 
__.__ 
Lean mass 
(lb.): 
__ __ 
__.__ femur (cm) 
__ __.__/__ 
__.__ 
 
 
 
Circumference  
Arms (cm): 
(R) __ __.__ / __ 
__.__ 
(L) __ __.__ / __ 
__.__ 
Thigh (cm): 
(R)__ __ __.__/ 
__ __ __.__ 
(L)__ __ __.__/ 
__ __ __.__ 
Calf (cm): 
(R) __ __.__ / __ 
__.__ 
(L) __ __.__ / __ 
__.__ 
Forearm 
(cm): 
(R) __ __.__ / __ 
__.__ 
(L) __ __.__ / __ 
__.__ 
Arms(Flx): 
(R) __ __.__ / __ 
__.__ male only 
shoulders 
(cm): 
__ __ __.__/ __ 
__ __.__ 
midax skf __ 
__.__ 
Chest (cm): 
__ __ __.__/ __ 
__ __.__ 
              __ 
__.__ 
Hip (cm): 
__ __ __.__/ __ 
__ __.__ female only 
Waist (cm): 
__ __ __.__/ __ 
__ __.__ 
bicep skf __ 
__.__ 
Femur length __ __.__/__ __.__ 
                   __ 
__.__ 
   
 
grip 
strength 
 
 
Right Left 
 First try     
 Second try     
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 One Repetition Max and Prescription     
* Follow instructions for maximal test      
        
  Max      80%    Max      80%  
1. Chest press: __ __     __ __ 
7. Tric. 
Extension: __ __     __ __  
2. Seated Row: __ __     __ __ 8. Arm curl: __ __     __ __  
3. Pull Down: __ __     __ __ 9.  Low Back: __ __     __ __  
4. Shoulder 
Press: __ __     __ __ 10.  Ab. Crunch: __ __     __ __  
5. Leg 
Extensions: __ __     __ __ 11. Incline Press: __ __     __ __  
6.  Leg curl:  __ __     __ __ 12. Leg Press __ __     __ __  
 
Sum Max _________    Avg% __________ 
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APPENDIX E 
GENES OF THE MTOR SIGNALING PATHWAY 
Gene SNP RS # 
Ref-
Homozygote Heterozygote 
Other-
Homozygote 
Ref-
Allele 
Other-
Allele 
       
INS rs3842748 G/G (0.050) C/G (0.040) C/C (0.550) G (0.250) C (0.750) 
       
IGF1 rs10860864 C/C (0.750) C/T (0.183) T/T (0.067) C (0.842) T (0.158) 
 rs5742667 T/T (0.083) C/T (0.283) C/C (0.633) T (0.225) C (0.775) 
 rs972936 A/A (0.083) A/G (0.283) G/G (0.633) A (0.225) G (0.775) 
 rs2373721 G/G (0.083) C/G (0.250) C/C (0.667) G (0.208) C (0.792) 
 rs11111272 G/G (0.119) C/G (0.288) C/C (0.593) G (0.263) C (0.737) 
 rs2288378 A/A (0.083) A/G (0.250) G/G (0.667) A (0.208) G (0.792) 
 rs10860865 T/T (0.085) G/T (0.288) G/G (0.627) T (0.229) G (0.771) 
 rs7296464 G/G (0.085) A/G (0.237) A/A (0.678) G (0.203) A (0.797) 
 rs7136446 C/C (0.233) C/T (0.367) T/T (0.400) C (0.417) T (0.583) 
 rs10735380 G/G (0.083) A/G (0.300) A/A (0.617) G (0.233) A (0.767) 
 rs9651925 G/G (0.000) G/T (0.288) T/T (0.712) G (0.144) T (0.856) 
 rs9989002 A/A (0.083) A/G (0.317) G/G (0.600) A (0.242) G (0.758) 
 rs4764697 T/T (0.083) C/T (0.300) C/C (0.617) T (0.233) C (0.767) 
 rs5742632 T/T (0.650) C/T (0.283) C/C (0.067) T (0.792) C (0.208) 
 rs2195240 T/T (0.650) C/T (0.283) C/C (0.067) T (0.792) C (0.208) 
 rs2195239 G/G (0.650) C/G (0.283) C/C (0.067) G (0.792) C (0.208) 
 rs5742629 A/A (0.567) A/G (0.333) G/G (0.100) A (0.733) G (0.267) 
 rs7956547 T/T (0.593) C/T (0.305) C/C (0.102) T (0.746) C (0.254) 
 rs10778176 C/C (0.567) C/T (0.350) T/T (0.083) C (0.742) T (0.258) 
 rs1019731 G/G (0.667) G/T (0.333) T/T (0.000) G (0.833) T (0.167) 
 rs10860869 A/A (0.576) A/T (0.339) T/T (0.085) A (0.746) T (0.254) 
 rs17796225 T/T (0.600) C/T (0.300) C/C (0.100) T (0.750) C (0.250) 
 rs12821878 G/G (0.517) A/G (0.383) A/A (0.100) G (0.708) A (0.292) 
 rs2162679 G/G (0.000) A/G (0.217) A/A (0.783) G (0.108) A (0.892) 
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Gene SNP RS # 
Ref-
Homozygote Heterozygote 
Other-
Homozygote 
Ref-
Allele 
Other-
Allele 
ERK1/2 
(MAPK1) rs9607287 A/A (0.317) A/G (0.400) G/G (0.283) A (0.517) G (0.483) 
 rs3788332 G/G (0.317) A/G (0.400) A/A (0.283) G (0.517) A (0.483) 
 rs2266969 G/G (0.383) A/G (0.367) A/A (0.250) G (0.567) A (0.433) 
 rs2283793 T/T (0.383) C/T (0.367) C/C (0.250) T (0.567) C(0.433) 
 rs9607298 G/G (0.383) C/G (0.367) C/C (0.250) G (0.567) C(0.433) 
 rs1892846 A/A (0.317) A/C (0.400) C/C (0.283) A (0.517) C(0.483) 
 rs1892848 T/T (0.317) C/T (0.400) C/C (0.283) T (0.517) C (0.483) 
 rs9610374 G/G (0.397) A/G (0.362) A/A (0.241) G (0.578) A (0.422) 
 rs9610375 G/G (0.317) G/T (0.417) T/T (0.267) G (0.525) T (0.475) 
 rs5999749 A/A (0.383) A/C (0.367) C/C (0.250) A (0.567) C (0.433) 
 rs5999752 G/G (0.383) A/G (0.367) A/A (0.250) G (0.567) A (0.433) 
 rs17759796 C/C (0.783) A/C (0.167) A/A (0.050) C (0.867) A (0.133) 
 rs9610417 C/C (0.600) C/T (0.283) T/T (0.117) C (0.742) T (0.258) 
 rs5755694 T/T (0.233) C/T (0.467) C/C (0.300) T (0.467) C (0.533) 
 rs8136867 G/G (0.267) A/G (0.433) A/A (0.300) G (0.483) A (0.517) 
 rs2876981 A/A (0.433) A/C (0.350) C/C (0.217) A (0.608) C (0.392) 
 rs9610470 T/T (0.567) C/T (0.317) C/C (0.117) T (0.725) C (0.275) 
 rs11913721 A/A (0.400) A/C (0.333) C/C (0.267) A (0.567) C (0.433) 
 rs2283794 T/T (0.333) C/T (0.383) C/C (0.283) T (0.525) C (0.475) 
 rs9610487 T/T (0.567) C/T (0.317) C/C (0.117) T (0.725) C (0.275) 
 rs4821402 G/G (0.317) A/G (0.400) A/A (0.283) G (0.517) A (0.483) 
 rs9610496 A/A (0.600) A/T (0.283) T/T (0.117) A (0.742) T (0.258) 
 rs5750113 C/C (0.333) C/T (0.383) T/T (0.283) C (0.525) T (0.475) 
RSK 
(RPS6KA6) rs1389465 A/A (0.150) A/G (0.233) G/G (0.617) A (0.267) G (0.733) 
 rs11092122 G/G (0.153) A/G (0.220) A/A (0.627) G (0.261) A (0.739) 
 rs1539517 G/G (0.150) C/G (0.233) C/C (0.617) G (0.267) C (0.733) 
 rs1544221 T/T (0.350) C/T (0.317) C/C (0.333) T (0.522) C (0.478) 
       
       
RSK 
(RPS6KA1) rs921893 G/G (0.100) A/G (0.300) A/A (0.600) G (0.250) A (0.750) 
 rs1466286 C/C (0.567) C/G (0.383) G/G (0.050) C (0.758) G (0.242) 
 rs12723936 A/A (0.480) A/G (0.500) G/G (0.020) A (0.730) G (0.270) 
 rs17162190 G/G (0.667) A/G (0.317) A/A (0.017) G (0.825) A (0.175) 
 rs2278978 A/A (0.100) A/G (0.300) G/G (0.600) A (0.250) G (0.750) 
 rs2278979 G/G (0.542) A/G (0.441) A/A (0.017) G (0.763) A (0.237) 
 rs897641 C/C (0.583) A/C (0.400) A/A (0.017) C (0.783) A (0.217) 
 rs3816540 A/A (0.650) A/C (0.267) C/C (0.083) A (0.783) C (0.217) 
 rs3790645 G/G (0.583) A/G (0.400) A/A (0.017) G (0.783) A (0.217) 
 rs444482 C/C (0.583) C/G (0.400) G/G (0.017) C (0.783) G (0.217) 
 rs392814 A/A (0.600) A/G (0.380) G/G (0.020) A (0.790) G (0.210) 
 rs369385 C/C (0.571) C/T (0.411) T/T (0.018) C (0.777) T (0.223) 
 rs11577405 G/G (0.421) G/T (0.491) T/T (0.088) G (0.667) T (0.333) 
 rs12402449 G/G (0.583) A/G (0.400) A/A (0.017) G (0.783) A (0.217) 
 rs282175 T/T (0.567) C/T (0.417) C/C (0.017) T (0.775) C (0.225) 
 rs188158 T/T (0.540) C/T (0.440) C/C (0.020) T (0.760) C (0.240) 
 rs282176 A/A (0.576) A/G (0.407) G/G (0.017) A (0.780) G (0.220) 
 rs282177 G/G (0.583) A/G (0.400) A/A (0.017) G (0.783) A (0.217) 
 rs190737 G/G (0.271) G/T (0.542) T/T (0.186) G (0.542) T (0.458) 
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Gene SNP RS # 
Ref-
Homozygote Heterozygote 
Other-
Homozygote 
Ref-
Allele 
Other-
Allele 
REDD1 
(DDIT4) rs1053639 T/T (0.483) A/T (0.483) A/A (0.033) T (0.725) A (0.275) 
       
PIK3R1 (PI3K) rs831125 A/A (0.797) A/G (0.169) G/G (0.034) A (0.881) G (0.119) 
 rs3730089 G/G (0.648) A/G (0.333) A/A (0.019) G (0.815) A (0.185) 
 rS12659907 G/G (0.817) A/G (0.183) A/A (0.000) G (0.908) A (0.092) 
 rs895304 G/G (0.673) A/G (0.309) A/A (0.018) G (0.827) A (0.173) 
 rs1445760 T/T (0.200) C/T (0.517) C/C (0.283) T (0.458) C (0.542) 
 rs1043526 A/A (0.750) A/G (0.250) G/G (0.000) A (0.875) G (0.125) 
 rs3756668 G/G (0.267) A/G (0.533) A/A (0.200) G (0.533) A (0.467) 
       
PDPK1 (PDK) rs7201584 T/T (0.70) C/T (0.283) C/C (0.017) T (0.842) C (0.158) 
 rs12447555 C/C (0.767) C/C (0.200) G/G (0.033) C (0.867) G (0.133) 
       
AKT1 (PKB) rs2494731 G/G (0.467) C/G (0.400) C/C (0.133) G (0.667) C (0.333) 
 rs3803304 G/G (0.633) C/G (0.283) C/C (0.083) G (0.775) C (0.225) 
 rs3001371 C/C (0.467) C/T (0.417) T/T (0.117) C (0.675) T (0.325) 
 rs1130214 G/G (0.517) G/T (0.417) T/T (0.067) G (0.725) T (0.275) 
 rs2494735 A/A (0.414) A/G (0.517) G/G (0.069) A (0.672) G (0.328) 
 rs1130233 G/G (0.677) A/G (0.258) A/A (0.065) G (0.806) A (0.194) 
TSC1 rs1073123 A/A (0.783) A/G (0.217) G/G (0.000) A (0.892) G (0.108) 
 rs7875422 G/G (0.817) A/G (0.183) A/A (0.000) G (0.908) A (0.092) 
 rs7865232 T/T (0.776) C/T (0.224) C/C (0.000) T (0.888) C (0.112) 
 rs7875558 G/G (0.783) A/G (0.217) A/A (0.000) G (0.892) A (0.108) 
 rs4367688 G/G (0.250) A/G (0.400) A/A (0.350) G (0.450) A (0.550) 
 rs7858160 C/C (0.767) C/T (0.233) T/T (0.000) C (0.883) T (0.117) 
 rs13295430 G/G (0.817) A/G (0.150) A/A (0.033) G (0.892) A (0.108) 
 rs13295634 G/G (0.083) G/T (0.350) T/T (0.567) G (0.258) T (0.742) 
 rs10901224 T/T (0.817) G/T (0.183) G/G (0.000) T (0.908) G (0.092) 
 rs3761840 A/A (0.283) A/G (0.383) G/G (0.333) A (0.475) G (0.525) 
 rs3827665 C/C (0.817) C/T (0.183) T/T (0.000) C (0.908) T (0.092) 
 rs10116061 C/C (0.250) C/T (0.400) T/T (0.350) C (0.450) T (0.550) 
 rs4419933 T/T (0.083) C/T (0.350) C/C (0.567) T (0.258) C (0.742) 
 rs7874234 C/C (0.633) C/T (0.350) T/T (0.017) C (0.808) T (0.192) 
 rs4469592 G/G (0.817) G/T (0.183) T/T (0.000) G (0.908) T (0.092) 
 rs883838 A/A (0.250) A/C (0.400) C/C (0.350) A (0.450) C (0.550) 
 rs7026607 A/A (0.633) A/G (0.350) G/G (0.017) A (0.808) G (0.192) 
       
TSC2 rs2073636 T/T (0.237) C/T (0.492) C/C (0.271) T (0.483) C (0.517) 
 rs2074968 C/C (0.283) C/G (0.483) G/G (0.233) C (0.525) G (0.475) 
 rs2074969 A/A (0.271) A/G (0.475) G/G (0.254) A (0.508) G (0.492) 
 rs8063461 A/A (0.217) A/G (0.533) G/G (0.250) A (0.483) G (0.517) 
 rs17654678 T/T (0.690) G/T (0.276) G/G (0.031) T (0.828) G (0.172) 
 rs30259 G/G (0.661) A/G (0.322) A/A (0.017) G (0.822) A (0.178) 
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Gene SNP RS # 
Ref-
Homozygote Heterozygote 
Other-
Homozygote 
Ref-
Allele Other-Allele 
PRKAA2 
(AMPK) rs1124900 T/T (0.300) G/T (0.533) G/G (0.167) T (0.567) G (0.433) 
 rs10789038 A/A (0.373) A/G (0.492) G/G (0.136) A (0.619) G (0.381) 
 rs11206889 C/C (0.367) C/T (0.500) T/T (0.133) C (0.617) T (0.383) 
 rs10711393 T/T (0.370) A/T (0.481) A/A (0.148) T (0.611) A (0.389) 
 rs4912408 G/G (0.352) A/G (0.407) A/A (0.241) G (0.556) A (0.444) 
 rs2143749 G/G (0.333) C/G (0.433) C/C (0.233) G (0.550) C (0.450) 
 rs11206890 T/T (0.356) C/T (0.508) C/C (0.136) T (0.610) C (0.390) 
 rs2746349 G/G (0.167) A/G (0.533) A/A (0.300) G (0.433) A (0.567) 
 rs10889008 G/G (0.367) A/G (0.500) A/A (0.133) G (0.617) A (0.383) 
 rs2796516 G/G (0.737) A/G (0.193) A/A (0.070) G (0.833) A (0.167) 
 rs2796519 A/A (0.133) A/G (0.500) G/G (0.367) A (0.383) G (0.617) 
 rs2746342 C/C (0.233) A/C (0.433) A/A (0.333) C (0.450) A (0.550) 
 rs2746339 T/T (0.167) C/T (0.533) C/C (0.300) T (0.433) C (0.567) 
 rs2796495 T/T (0.167) C/T (0.533) C/C (0.300) T (0.433) C (0.567) 
 rs2796498 A/A (0.167) A/G (0.533) G/G (0.300) A (0.433) G (0.567) 
 rs2092595 G/G (0.183) G/T (0.500) T/T (0.317) G (0.433) T (0.567) 
 rs2796512 A/A (0.186) A/G (0.508) G/G (0.305) A (0.441) G (0.559) 
 rs2796509 C/C (0.183) C/T (0.500) T/T (0.317) C (0.433) T (0.567) 
 rs1418442 A/A (0.367) A/G (0.500) G/G (0.133) A (0.617) G (0.383) 
 rs857155 A/A (0.186) A/C (0.492) C/C (0.322) A (0.432) C (0.568) 
 rs932447 A/A (0.367) A/G (0.500) G/G (0.133) A (0.617) G (0.383) 
       
LKB1 rs664254 G/G (0.330) C/G (0.500) C/C (0.200) G (0.550) C (0.450) 
 rs673951 C/C (0.300) C/T (0.483) T/T (0.217) C (0.542) T (0.458) 
 rs2305052 G/G (0.533) G/T (0.333) T/T (0.133) G (0.700) T (0.300) 
STRAD 
(LYK5) rs13380863 G/G (0.450) A/G (0.450) A/A (0.100) G (0.675) A (0.325) 
 rs721575 G/G (0.217) A/G (0.500) A/A (0.283) G (0.467) A (0.533) 
 rs9944483 T/T (0.418) G/T (0.545) G/G (0.036) T (0.691) G (0.039) 
 rs3817182 T/T (0.119) C/T (0.475) C/C (0.407) T (0.356) C (0.644) 
 rs2013288  C/C (0.450) C/T (0.450) T/T (0.100) C (0.675) T (0.325) 
 rs16947051 G/G (0.433) C/G (0.533) C/C (0.033) G (0.700) C (0.300) 
 rs1043127 A/A (0.133) A/C (0.483) C/C (0.383) A (0.375) C (0.625) 
 rs1982400 T/T (0.133) C/T (0.483) C/C (0.383) T (0.375) C (0.625) 
 rs7210724 T/T (0.107) C/T (0.500) C/C (0.393) T (0.357) C (0.643) 
 rs1470697 T/T (0.133) C/T (0.483) C/C (0.383) T (0.375) C (0.625) 
 rs8075422 G/G (0.458) A/G (0.458) A/A (0.085) G (0.686) A (0.314) 
 rs2137144 G/G (0.123) A/G (0.491) A/A (0.386) G (0.368) A (0.632) 
 rs6504177 G/G (0.133) A/G (0.483) A/A (0.383) G (0.375) A (0.625) 
 rs6504179 T/T (0.117) G/T (0.467) G/G (0.417) T (0.350) G (0.650) 
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Ref-
Allele Other-Allele 
MO25 
(CAB39) rs10168275 C/C (0.633) C/T (0.367) T/T (0.000) C (0.817) T (0.183) 
 rs2720162 G/G (0.200) G/T (0.467) T/T (0.333) G (0.433) T (0.567) 
 rs1464205 T/T (0.400) C/T (0.450) C/C (0.150) T (0.625) C (0.375) 
 rs7564854 G/G (0.733) A/G (0.250) A/A (0.017) G (0.858) A (0.142) 
 rs6733332 T/T (0.627) C/T (0.356) C/C (0.017) T (0.805) C (0.195) 
 rs6436972 A/A (0.633) A/G (0.350) G/G (0.017) A (0.808) G (0.192) 
 rs6750664 G/G (0.633) A/G (0.350) A/A (0.017) G (0.808) A (0.192) 
 rs2438296 G/G (0.150) G/T (0.467) T/T (0.383) G (0.383) T (0.617) 
 rs3792076 G/G (0.633) A/G (0.350) A/A (0.017) G (0.808) A (0.192) 
 rs3792074 A/A (0.633) A/G (0.350) G/G (0.017) A (0.808) G (0.192) 
 rs2438298 A/A (0.617) A/G (0.267) G/G (0.117) A (0.750) G (0.250) 
 rs3792069 G/G (0.733) A/G (0.233) A/A (0.033) G (0.850) A (0.150) 
 rs3792071 G/G (0.633) A/G (0.367) A/A (0.000) G (0.817) A (0.183) 
       
       
GβL rs26863 G/G (0.267) C/G (0.500) C/C (0.233) G (0.517) C (0.483) 
 rs26862 C/C (0.271) C/G (0.475) G/G (0.254) C (0.508) G (0.492) 
       
MTOR 
(FRAP1) rs11121695 G/G (0.533) A/G (0.433) A/A (0.033) G (0.750) A (0.250) 
 rs11585553 G/G (0.533) A/G (0.433) A/A (0.033) G (0.750) A (0.250) 
 rs10864490 G/G (0.533) A/G (0.433) A/A (0.033) G (0.750) A (0.250) 
 rs6674994 T/T (0.033) C/T (0.433) C/C (0.533) T (0.250) C (0.750) 
 rs4845982 T/T (0.019) C/T (0.500) C/C (0.481) T (0.269) C (0.731) 
 rs2300095 T/T (0.067) C/T (0.483) C/C (0.450) T (0.308) C (0.692) 
 rs1010447 T/T (0.050) C/T (0.483) C/C (0.467) T (0.292) C (0.708) 
 rs4845856 T/T (0.050) C/T (0.483) C/C (0.467) T (0.292) C (0.708) 
 rs7526649 C/C (0.050) C/T (0.483) T/T (0.467) C (0.292) T (0.708) 
 rs7549109 G/G (0.050) C/G (0.483) C/C (0.467) G (0.292) C (0.708) 
 rs10779751 A/A (0.050) A/G (0.483) G/G (0.467) A (0.292) G (0.708) 
 rs12124983 T/T (0.050) C/T (0.483) C/C (0.467) T (0.292) C (0.708) 
 rs1064261 C/C (0.050) C/T (0.483) T/T (0.467) C (0.292) T (0.708) 
 rs2076655 G/G (0.050) A/G (0.483) A/A (0.467) G (0.292) A (0.708) 
 rs11121704 C/C (0.052) C/T (0.483) T/T (0.466) C (0.293) T (0.707) 
 rs718206 T/T (0.050) A/T (0.483) A/A (0.467) T (0.292) A (0.708) 
 rs2024627 T/T (0.050) C/T (0.483) C/C (0.467) T (0.292) C (0.708) 
 rs7544489 C/C (0.050) C/T (0.483) T/T (0.467) C (0.292) T (0.708) 
 rs11121705 A/A (0.050) A/G (0.500) G/G (0.450) A (0.300) G (0.700) 
 rs11121706 G/G (0.050) A/G (0.483) A/A (0.467) G (0.292) A (0.708) 
 rs1205592 C/C (0.050) C/T (0.483) T/T (0.467) C (0.292) T (0.708) 
 rs7364685 C/C (0.050) C/T (0.483) T/T (0.467) C (0.292) T (0.708) 
 rs7525957 C/C (0.050) C/T (0.483) T/T (0.467) C (0.292) T (0.708) 
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RICTOR rs13161443 A/A (0.615) A/G (0.346) G/G (0.038) A (0.788) G (0.212) 
 rs13166875 A/A (0.400) A/G (0.367) G/G (0.233) A (0.583) G (0.417) 
 rs1239274 G/G (0.339) C/G (0.407) C/C (0.254) G (0.542) C (0.458) 
 rs1239276 T/T (0.367) C/T (0.383) C/C (0.250) T (0.558) C (0.442) 
 rs10472314 A/A (0.085) A/G (0.542) G/G (0.373) A (0.356) G (0.644) 
 rs9292729 C/C (0.103) C/T (0.517) T/T (0.379) C (0.362) T (0.638) 
 rs7713236 G/G (0.100) A/G (0.533) A/A (0.367) G (0.367) A (0.633) 
 rs6878291 G/G (0.373) A/G (0.390) A/A (0.237) G (0.568) A (0.432) 
 rs10078168 G/G (0.100) G/T (0.533) T/T (0.367) G (0.367) T (0.633) 
 rs13168966 C/C (0.367) A/C (0.383) A/A (0.250) C (0.558) A (0.442) 
 rs7719775 A/A (0.100) A/G (0.533) G/G (0.367) A (0.367) G (0.633) 
 rs12233987 T/T (0.417) C/T (0.350) C/C (0.233) T (0.592) C (0.408) 
 rs10473128 A/A (0.083) A/G (0.550) G/G (0.367) A (0.358) G (0.642) 
 rs13160161 G/G (0.417) A/G (0.400) A/A (0.183) G (0.617) A (0.383) 
       
Rheb rs3753151 C/C (0.167) C/T (0.517) T/T (0.317) C (0.425) T (0.575) 
 rs13224450 G/G (0.070) A/G (0.316) A/A (0.614) G (0.228) A (0.772) 
 rs2299965 C/C (0.217) C/T (0.517) T/T (0.267) C (0.475) T (0.525) 
 rs7810890 T/T (0.217) C/T (0.517) C/C (0.267) T (0.475) C (0.525) 
 rs11772458 G/G (0.231) C/G (0.577) C/C (0.192) G (0.519) C (0.481) 
 rs3087741 A/A (0.150) A/G (0.500) G/G (0.350) A (0.400) G (0.600) 
 rs2299967 T/T (0.220) C/T (0.508) C/C (0.271) T (0.475) C (0.525) 
 rs3789817 G/G (0.217) A/G (0.517) A/A (0.267) G (0.475) A (0.525) 
 rs758666 C/C (0.217) C/T (0.517) T/T (0.267) C (0.475) T (0.525) 
 rs736645 G/G (0.217) G/T (0.517) T/T (0.267) G (0.475) T (0.525) 
 rs4298422 G/G (0.211) A/G (0.526) A/A (0.263) G (0.474) A (0.526) 
 rs2374261 C/C (0.217) C/T (0.517) T/T (0.267) C (0.475) T (0.525) 
 rs12112989 C/C (0.217) C/T (0.517) T/T (0.267) C (0.475) T (0.525) 
 rs6980020 T/T (0.217) G/T (0.517) G/G (0.267) T (0.475) G (0.525) 
 rs12112134 A/A (0.224) A/G (0.500) G/G (0.276) A (0.474) G (0.526) 
 rs6948196 T/T (0.217) C/T (0.517) C/C (0.267) T (0.475) C (0.525) 
 rs6943752 A/A (0.237) A/G (0.475) G/G (0.288) A (0.475) G (0.525) 
 
Raptor rs7213696 G/G (0.317) A/G (0.517) A/A (0.167) G (0.575) A (0.425) 
 rs4602089 A/A (0.491) A/G (0.439) G/G (0.070) A (0.711) G (0.289) 
 rs12942526 A/A (0.190) A/G (0.517) G/G (0.293) A (0.448) G (0.552) 
 rs12601089 C/C (0.483) C/T (0.433) T/T (0.083) C (0.700) T (0.300) 
 rs9899782 G/G (0.600) A/G (0.300) A/A (0.100) G (0.750) A (0.250) 
 rs4396582 A/A (0.183) A/G (0.533) G/G (0.283) A (0.450) G (0.550) 
 rs9902639 A/A (0.183) A/G (0.533) G/G (0.283) A (0.450) G (0.550) 
 rs4969230 T/T (0.350) C/T (0.517) C/C (0.133) T (0.608) C (0.392) 
 rs2291359 G/G (0.492) A/G (0.441) A/A (0.068) G (0.712) A (0.288) 
 rs4969235 A/A (0.350) A/T (0.517) T/T (0.133) A (0.608) T (0.392) 
 rs9895584 A/A (0.600) A/G (0.291) G/G (0.109) A (0.745) G (0.255) 
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 rs12950541 G/G (0.483) A/G (0.433) A/A (0.083) G (0.700) A (0.300) 
 rs12450464 G/G (0.607) A/G (0.304) A/A (0.089) G (0.759) A (0.241) 
 rs9913009 T/T (0.617) C/T (0.283) C/C (0.100) T (0.758) C (0.242) 
 rs9901049 T/T (0.610) G/T (0.288) G/G (0.102) T (0.754) G (0.246) 
 rs12943552 C/C (0.483) C/T (0.450) T/T (0.067) C (0.708) T (0.292) 
 rs9915518 G/G (0.610) A/G (0.288) A/A (0.102) G (0.754) A (0.246) 
 rs7213638 C/C (0.600) C/T (0.300) T/T (0.100) C (0.750) T (0.250) 
 rs9890313 C/C (0.600) C/T (0.300) T/T (0.100) C (0.750) T (0.250) 
 rs9989484 T/T (0.593) G/T (0.305) G/G (0.102) T (0.746) G (0.254) 
 rs9891139 A/A (0.600) A/G (0.300) G/G (0.100) A (0.750) G (0.250) 
 rs9894401 G/G (0.600) A/G (0.283) A/A (0.117) G (0.742) A (0.258) 
 rs9897830 A/A (0.579) A/G (0.316) G/G (0.105) A (0.737) G (0.263) 
 rs9895847  G/G (0.625) A/G (0.268) A/A (0.107) G (0.759) A (0.241) 
 rs4380096 A/A (0.467) A/G (0.467) G/G (0.067) A (0.700) G (0.300) 
 rs7208831 G/G (0.600) G/T (0.300) T/T (0.100) G (0.750) T (0.250) 
 rs7216268 C/C (0.600) A/C (0.300) A/A (0.100) C (0.750) A (0.250) 
 rs9989446 A/A (0.600) A/G (0.300) G/G (0.100) A (0.750) G (0.250) 
 rs7216295 C/C (0.593) C/T (0.305) T/T (0.102) C (0.746) T (0.254) 
 rs4969404 C/C (0.333) C/T (0.519) T/T (0.148) C (0.593) T (0.407) 
 rs12947507 G/G (0.500) A/G (0.448) A/A (0.052) G (0.724) A (0.276) 
 rs9900956 T/T (0.600) C/T (0.300) C/C (0.100) T (0.750) C (0.250) 
 rs7221492 C/C (0.600) A/C (0.300) A/A (0.100) C (0.750) A (0.250) 
 rs12941973 C/C (0.500) C/T (0.448) T/T (0.052) C (0.724) T (0.276) 
 rs8064506 T/T (0.600) C/T (0.300) C/C (0.100) T (0.750) C (0.250) 
 rs12452243 A/A (0.593) A/G (0.305) G/G (0.102) A (0.746) G (0.254) 
 rs8077901 G/G (0.621) G/T (0.293) T/T (0.086) G (0.767) T (0.233) 
 rs7208536 C/C (0.610) C/T (0.288) T/T (0.102) C (0.754) T (0.246) 
 rs7208971 A/A (0.593) A/T (0.305) T/T (0.102) A (0.746) T (0.254) 
 rs9910524 C/C (0.600) C/G (0.300) G/G (0.100) C (0.750) G (0.250) 
 rs9898483 T/T (0.586) C/T (0.310) C/C (0.103) T (0.741) C (0.259) 
 rs9898212 A/A (0.600) A/C (0.300) C/C (0.100) A (0.750) C (0.250) 
 rs9898441 A/A (0.600) A/C (0.300) C/C (0.100) A (0.750) C (0.250) 
 rs6565480 A/A (0.600) A/G (0.300) G/G (0.100) A (0.750) G (0.250) 
 rs11150746 A/A (0.473) A/G (0.364) G/G (0.164) A (0.655) G (0.345) 
 rs4969266  C/C (0.583) C/T (0.400) T/T (0.017) C (0.783) T (0.217) 
 rs11150747 C/C (0.612) C/T (0.347) T/T (0.041) C (0.786) T (0.214) 
 rs4969426 A/A (0.125) A/T (0.411) T/T (0.464) A (0.330) T (0.667) 
 rs719781 G/G (0.527) A/G (0.418) A/A (0.055) G (0.736) A (0.264) 
 rs4969429 A/A (0.050) A/G (0.367) G/G (0.583) A (0.233) G (0.767) 
 rs8069962 G/G (0.172) A/G (0.534) A/A (0.293) G (0.440) A (0.560) 
 rs12953234 G/G (0.298) A/G (0.509) A/A (0.193) G (0.553) A (0.447) 
 rs12601434 C/C (0.517) C/G (0.433) G/G (0.050) C (0.733) G (0.267) 
 rs2589138 C/C (0.576) C/T (0.390) T/T (0.034) C (0.771) T (0.229) 
 rs11654508 A/A (0.517) A/G (0.433) G/G (0.050) A (0.733) G (0.267) 
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 rs9905648 C/C (0.733) C/G (0.200) G/G (0.067) C (0.833) G (0.167) 
 rs2672886 T/T (0.267) C/T (0.550) C/C (0.183) T (0.542) C (0.458) 
 rs734338 G/G (0.300) A/G (0.417) A/A (0.283) G (0.508) A (0.492) 
 rs2138125 T/T (0.283) C/T (0.417) C/C (0.300) T (0.492) C (0.508) 
 rs2271612 C/C (0.133) C/T (0.483) T/T (0.383) C (0.375) T (0.625) 
 rs4969311 C/C (0.117) C/G (0.483) G/G (0.400) C (0.358) G (0.642) 
 rs9899051 A/A (0.118) A/G (0.529) G/G (0.353) A (0.383) G (0.618) 
 rs868432 C/C (0.417) C/T (0.433) T/T (0.150) C (0.633) T (0.367) 
HIF1α rs2301106 T/T (0.810) C/T (0.172) C/C (0.017) T (0.897) C (0.103) 
 rs1951795 A/A (0.017) A/C (0.271) C/C (0.712) A (0.153) C (0.847) 
 rs12435848 A/A (0.017) A/G (0.267) G/G (0.717) A (0.150) G (0.850) 
 rs12434438 G/G (0.017) A/G (0.283) A/A (0.700) G (0.158) A (0.842) 
 rs11158358 G/G (0.017) C/G (0.233) C/C (0.750) G (0.133) C (0.867) 
 rs2301111 G/G (0.017) C/G (0.283) C/C (0.695) G (0.161) C (0.839) 
 rs10873142 C/C (0.018) C/T (0.263) T/T (0.719) C (0.149) T (0.851) 
 rs2301113 C/C (0.017) A/C (0.333) A/A (0.650) C (0.183) A (0.817) 
       
RPS6KB2 
(P70S6K) rs1476792 T/T (0.267) C/T (0.55) C/C (0.183) T (0.542) C (0.458) 
 rs917570 C/C (0.317) C/G (0.517) G/G (0.167) C (0.575) G (0.425) 
 rs1638588 C/C (0.267) A/C (0.55) A/A (0.183) C (0.542) A (0.458) 
 rs1790753 G/G (0.267) A/G (0.55) A/A (0.183) G (0.542) A (0.458) 
       
ATG1 (ULK3) rs2290573 C/C (0.237) C/T (0.424) T/T (0.339) C (0.449) T (0.551) 
 rs2290572 T/T (0.167) C/T (0.400) C/C (0.433) T (0.367) C (0.633) 
 rs936227 A/A (0.153) A/G (0.407) G/G (0.441) A (0.356) G (0.644) 
 rs936229 A/A (0.000) A/G (0.327) G/G (0.673) A (0.163) G (0.837) 
 rs12908814 C/C (0.167) C/G (0.426) G/G (0.407) C (0.380) G (0.620) 
       
VEGF-CD 
(FIGF) rs6527518 G/G (0.500) G/T (0.150) T/T (0.350) G (0.578) T (0.422) 
 rs6629030 A/A (0.717) A/G (0.117) G/G (0.167) A (0.778) G (0.222) 
 rs6632474 T/T (0.717) C/T (0.117) C/C (0.167) T (0.778) C (0.222) 
 rs6418686 T/T (0.633) C/T (0.133) C/C (0.233) T (0.700) C (0.300) 
 rs6629049 G/G (0.732) G/T (0.125) T/T (0.143) G (0.791) T (0.209) 
 rs4830939 A/A (0.300) A/G (0.233) G/G (0.467) A (0.422) G (0.578) 
 rs6632519 C/C (0.660) C/T (0.170) T/T (0.170) C (0.763) T (0.237) 
VEGF-AB 
(PGF) rs1042886 C/C (0.778) A/C (0.204) A/A (0.019) C (0.880) A (0.120) 
 rs8185 A/A (0.678) A/G (0.305) G/G (0.017) A (0.831) G (0.169) 
 rs12411 T/T (0.018) A/T (0.327) A/A (0.655) T (0.182) A (0.818) 
 rs2359192 C/C (0.018) A/C (0.357) A/A (0.625) C (0.196) A (0.804) 
 rs2268614 C/C (0.367) C/T (0.517) T/T (0.117) C (0.625) T (0.375) 
 rs2268615 C/C (0.350) A/C (0.517) A/A (0.133) C (0.608) A (0.392) 
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 rs17691581 A/A (0.448) A/G (0.448) G/G (0.103) A (0.672) G (0.328) 
 rs2037415 G/G (0.842) A/G (0.158) A/A (0.000) G (0.921) A (0.079) 
 rs12582526  C/C (0.667) C/T (0.300) T/T (0.033) C (0.817) T (0.183) 
 rs17122378 T/T (0.842) C/T (0.158) C/C (0.000) T (0.921) C (0.079) 
       
S6 (RPS6) rs957 C/C (0.817) C/T (0.183) T/T (0.000) C (0.908) T (0.092) 
       
EIF4E rs4699369 G/G (0.517) A/G (0.433) A/A (0.050) G (0.733) A (0.267) 
 rs4699689 C/C (0.564) C/T (0.382) T/T (0.055) C (0.755) T (0.245) 
 rs6830125 G/G (0.362) C/G (0.517) C/C (0.121) G (0.621) C (0.379) 
 rs13110878 A/A (0.517) A/C (0.433) C/C (0.050) A (0.733) C (0.267) 
 rs11735758 T/T (0.517) A/T (0.433) A/A (0.050) T (0.733) A (0.267) 
 rs11736580 T/T (0.517) C/T (0.433) C/C (0.050) T (0.733) C (0.267) 
 rs10023577 G/G (0.367) A/G (0.500) A/A (0.133) G (0.617) A (0.383) 
 rs12498533 A/A (0.367) A/C (0.500) C/C (0.133) A (0.617) C (0.383) 
 rs17570252 T/T (0.525) C/T (0.424) C/C (0.051) T (0.737) C (0.263) 
 rs17028241 A/A (0.845) A/G (0.155) G/G (0.000) A (0.922) G (0.078) 
 rs17583053 C/C (0.517) C/T (0.433) T/T (0.050) C (0.733) T (0.267) 
 rs6852715 C/C (0.367) C/T (0.500) T/T (0.133) C (0.617) T (0.383) 
 rs11727079 A/A (0.508) A/G (0.441) G/G (0.051) A (0.729) G (0.271) 
 rs11727086 A/A (0.517) A/G (0.433) G/G (0.050) A (0.733) G (0.267) 
       
     
Source: 
Hapmap.org 
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APPENDIX F 
INDIVIDUAL COMPONENTS OF ARM MASS-ADJUSTED STRENGTH BY 
GENOTYPE 
Table 21Individual Components of Arm Mass-Adjusted Strength by rs2494735 Genotype 
 AA AG GG 
Pre-RET 1 RM Biceps (kg) 40.34 ± 21.74 40.08 ± 22.12 40.00 ± 19.32 
Post-RET 1 RM Biceps (kg) 53.40 ± 23.67 55.76 ± 25.27 54.69 ± 23.05 
Pre-RET 1 RM Triceps (kg) 49.10 ± 21.00 51.78 ± 23.30 51.25 ± 20.78 
Post-RET 1 RM Triceps (kg) 68.06 ± 23.78 70.25 ± 26.15 68.43 ± 23.86 
Pre-RET Arm Circ. (cm) 29.68 ± 4.41 29.98 ± 3.55 30.67 ± 3.61 
Post-RET Arm Circ. (cm) 30.70 ± 3.97 31.18 ± 3.48 32.24 ± 3.55 
Arm mass-adjusted strength = (1 RM biceps + 1 RM triceps) / arm circumference. 
Values are Means ± SD 
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Table 22 Individual Components of Arm Mass-Adjusted Strength by rs1130233 Genotype 
 GG AG AA 
Pre-RET 1 RM Biceps (kg) 42.34±22.50 37.29±20.50  38.13±18.31  
Post-RET 1 RM Biceps (kg) 56.72±24.42  52.29±23.43  53.75±26.56  
Pre-RET 1 RM Triceps (kg) 51.88±21.87  48.96±22.50  50.00±21.88 
Post-RET 1 RM Triceps (kg) 70.55±23.99  67.50±25.76  68.75±25.17 
Pre-RET Arm Circ. (cm) 29.83±4.07  30.04±3.55  30.67±3.99  
Post-RET Arm Circ. (cm) 30.95±3.75  31.25±3.43  32.10±4.27 
Arm mass-adjusted strength = (1 RM biceps + 1 RM triceps) / arm circumference. 
Values are Means ± SD 
 
 
Table 23 Individual Components of Arm Mass-Adjusted Strength by rs3001371 Genotype 
 CC CT TT 
Pre-RET 1 RM Biceps (kg) 41.81±22.45 38.98±21.66  38.86±17.59  
Post-RET 1 RM Biceps (kg) 55.45±23.93  54.55±25.19  53.86±22.14  
Pre-RET 1 RM Triceps (kg) 51.27±21.91  50.68±23.09  49.55±20.70 
Post-RET 1 RM Triceps (kg) 70.18±24.38  68.64±26.09  69.09±23.89 
Pre-RET Arm Circ. (cm) 29.86±4.26  29.64±3.78  31.02±2.89  
Post-RET Arm Circ. (cm) 30.95±3.95  30.68±3.54  32.74±3.07 
Arm mass-adjusted strength = (1 RM biceps + 1 RM triceps) / arm circumference. 
Values are Means ± SD 
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Table 24 Individual Components of Arm Mass-Adjusted Strength by rs1130214 Genotype 
 GG GT TT 
Pre-RET 1 RM Biceps (kg) 43.09±21.07 38.77±21.03  33.84±23.02  
Post-RET 1 RM Biceps (kg) 58.36±24.51  52.45±23.40  47.30±24.29  
Pre-RET 1 RM Triceps (kg) 54.45±22.35  48.40±21.16  44.62±22.50 
Post-RET 1 RM Triceps (kg) 75.00±24.57  65.85±24.54  59.62±22.95 
Pre-RET Arm Circ. (cm) 30.49±4.33  29.65±3.49  29.28±3.29  
Post-RET Arm Circ. (cm) 31.60±4.07  30.95±3.42  30.39±3.16 
Arm mass-adjusted strength = (1 RM biceps + 1 RM triceps) / arm circumference. 
Values are Means ± SD 
 
 
Table 25 Individual Components of Arm Mass-Adjusted Strength by rs1124900 Genotype 
 TT GT GG 
Pre-RET 1 RM Biceps (kg) 38.64±19.25 42.05±25.54  38.71±19.92  
Post-RET 1 RM Biceps (kg) 54.69±24.14  56.16±24.42  52.90±23.87  
Pre-RET 1 RM Triceps (kg) 50.76±21.18  52.14±23.25  48.22±21.31 
Post-RET 1 RM Triceps (kg) 70.76±26.31  69.55±24.70  67.90±24.31 
Pre-RET Arm Circ. (cm) 30.37±3.75  29.80±4.03  29.78±3.86  
Post-RET Arm Circ. (cm) 31.64±3.83  31.05±3.72  30.84±3.73 
Arm mass-adjusted strength = (1 RM biceps + 1 RM triceps) / arm circumference. 
Values are Means ± SD 
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Table 26 Individual Components of Arm Mass-Adjusted Strength by rs2796516 Genotype  
 GG AG AA* 
Pre-RET 1 RM Biceps (kg) 39.76±21.17 41.36±22.44  50.00  
Post-RET 1 RM Biceps (kg) 54.35±23.85  55.15±23.89  100.00  
Pre-RET 1 RM Triceps (kg) 50.58±22.68  50.75±20.35  70.00 
Post-RET 1 RM Triceps (kg) 69.52±25.60  67.58±21.87  110.00 
Pre-RET Arm Circ. (cm) 30.01±3.76  29.71±4.04  36.45  
Post-RET Arm Circ. (cm) 31.16±3.53  30.91±3.84  38.60 
Arm mass-adjusted strength = (1 RM biceps + 1 RM triceps) / arm circumference. 
Values are Means ± SD.  * AA genotype N = 1. 
 
 
Table 27 Individual Components of Arm Mass-Adjusted Strength by rs1418442 Genotype  
 AA AG GG 
Pre-RET 1 RM Biceps (kg) 37.65±19.90 41.89±22.62  38.00±16.97  
Post-RET 1 RM Biceps (kg) 52.35±24.25  55.74±23.54  54.50±24.86  
Pre-RET 1 RM Triceps (kg) 48.97±20.07  51.97±23.24  48.50±20.46 
Post-RET 1 RM Triceps (kg) 67.94±25.71  69.67±23.77  69.00±26.18 
Pre-RET Arm Circ. (cm) 29.80±3.76  29.79±4.17  30.27±3.64  
Post-RET Arm Circ. (cm) 30.92±3.60  30.99±3.89  31.46±3.72 
Arm mass-adjusted strength = (1 RM biceps + 1 RM triceps) / arm circumference. 
Values are Means ± SD 
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APPENDIX G 
INDIVIDUAL COMPONENTS OF LEG MASS-ADJUSTED STRENGTH BY 
GENOTYPE 
Table 28 Individual Components of Leg Mass-Adjusted Strength by rs2494735 Genotype 
 AA AG GG 
Pre-RET 1 RM Hamstring (kg) 90.23±32.01 93.56±31.88  91.56±37.22  
Post-RET 1 RM Hamstring (kg) 108.07±35.75 113.98±36.89 112.81±34.06 
Pre-RET 1 RM Leg Ext. (kg) 165.38±55.55  174.78±62.62 158.48±69.74 
Post-RET 1 RM Leg Ext. (kg) 235.48±62.36  247.56±80.09  221.89±78.27 
Pre-RET Thigh Circ. (cm) 55.17±5.67  54.96±5.47  55.84±5.91  
Post-RET Thigh Circ. (cm) 55.18±5.22  55.97±5.14  57.22±5.71 
Leg mass-adjusted strength = (1 RM hamstring curl + 1 RM leg extension) /  
thigh circumference. Values are Means ± SD. 
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Table 29 Individual Components of Leg Mass-Adjusted Strength by rs1130233 Genotype  
 GG AG AA 
Pre-RET 1 RM Hamstring (kg) 93.67±31.59 89.79±33.15  91.25±36.42  
Post-RET 1 RM Hamstring (kg) 113.67±37.25 109.06±33.30 110.62±39.32 
Pre-RET 1 RM Leg Ext. (kg) 173.86±59.38 162.52±58.07 175.08±87.98 
Post-RET 1 RM Leg Ext. (kg) 246.38±68.25 233.94±76.00 235.34±100.45 
Pre-RET Thigh Circ. (cm) 54.96±5.56  55.71±5.67  54.89±4.48  
Post-RET Thigh Circ. (cm) 55.54±5.09  56.38±5.46  56.03±4.50 
Leg mass-adjusted strength = (1 RM hamstring curl + 1 RM leg extension) /  
thigh circumference. Values are Means ± SD. 
 
 
Table 30 Individual Components of Leg Mass-Adjusted Strength by rs3001371 Genotype  
 CC CT TT 
Pre-RET 1 RM Hamstring (kg) 94.00±32.93 88.63±33.49  95.00±31.32  
Post-RET 1 RM Hamstring (kg) 111.73±35.71 111.70±37.69 112.50±34.52 
Pre-RET 1 RM Leg Ext. (kg) 170.42±57.74  164.52±58.64 177.60±74.52 
Post-RET 1 RM Leg Ext. (kg) 244.93±68.98  236.46±78.66  240.94±80.63 
Pre-RET Thigh Circ. (cm) 54.97±5.58  55.04±5.60  56.46±5.42  
Post-RET Thigh Circ. (cm) 55.31±5.02  55.71±5.33  57.91±5.18 
Leg mass-adjusted strength = (1 RM hamstring curl + 1 RM leg extension) /  
thigh circumference. Values are Means ± SD. 
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Table 31 Individual Components of Leg Mass-Adjusted Strength by rs1130214 Genotype 
 GG GT TT 
Pre-RET 1 RM Hamstring (kg) 96.91±34.26 90.19±30.03  81.53±34.84  
Post-RET 1 RM Hamstring (kg) 118.18±38.65 107.55±33.71 101.92±30.72 
Pre-RET 1 RM Leg Ext. (kg) 182.33±67.34  162.29±53.40 145.36±53.69 
Post-RET 1 RM Leg Ext. (kg) 254.49±75.21  235.51±71.30  204.04±72.67 
Pre-RET Thigh Circ. (cm) 56.47±5.75  54.72±5.30  52.97±3.61  
Post-RET Thigh Circ. (cm) 56.86±5.57  55.45±5.00  54.07±3.56 
Leg mass-adjusted strength = (1 RM hamstring curl + 1 RM leg extension) /  
thigh circumference. Values are Means ± SD. 
 
 
Table 32 Individual Components of Leg Mass-Adjusted Strength by rs1124900 Genotype 
 TT GT GG 
Pre-RET 1 RM Hamstring (kg) 91.21±33.38 92.68±33.60  92.90±31.80  
Post-RET 1 RM Hamstring (kg) 110.90±37.24 113.48±34.94 110.97±37.18 
Pre-RET 1 RM Leg Ext. (kg) 179.64±74.43  168.70±59.88 162.88±44.87 
Post-RET 1 RM Leg Ext. (kg) 256.53±84.09  238.10±71.60  233.29±66.16 
Pre-RET Thigh Circ. (cm) 56.16±4.94  55.00±5.89  54.64±5.68  
Post-RET Thigh Circ. (cm) 57.22±4.97  55.61±5.36  55.12±5.21 
Leg mass-adjusted strength = (1 RM hamstring curl + 1 RM leg extension) /  
thigh circumference. Values are Means ± SD. 
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Table 33 Individual Components of Leg Mass-Adjusted Strength by rs2796516 Genotype  
 GG AG AA* 
Pre-RET 1 RM Hamstring (kg) 92.35±32.84 91.52±31.19  115.00  
Post-RET 1 RM Hamstring (kg) 110.71±35.81 113.18±35.51 160.00 
Pre-RET 1 RM Leg Ext. (kg) 167.52±60.47  174.39±63.13 205.00 
Post-RET 1 RM Leg Ext. (kg) 234.63±72.13  251.45±75.97  373.30 
Pre-RET Thigh Circ. (cm) 55.18±5.23  54.69±5.91  69.25  
Post-RET Thigh Circ. (cm) 55.66±4.91  55.81±5.41  71.58 
Leg mass-adjusted strength = (1 RM hamstring curl + 1 RM leg extension) /  
thigh circumference. Values are Means ± SD. * AA genotype N = 1. 
 
 
Table 34 Individual Components of Leg Mass-Adjusted Strength by rs1418442 Genotype  
 AA AG GG 
Pre-RET 1 RM Hamstring (kg) 88.82±32.48 91.39±32.43  98.50±32.89  
Post-RET 1 RM Hamstring (kg) 109.41±39.50 112.30±33.97 111.75±38.43 
Pre-RET 1 RM Leg Ext. (kg) 174.91±65.12  163.23±57.80 178.26±65.09 
Post-RET 1 RM Leg Ext. (kg) 245.15±77.14  229.76±69.23  258.15±80.32 
Pre-RET Thigh Circ. (cm) 55.44±4.89  54.54±5.77  56.26±6.16  
Post-RET Thigh Circ. (cm) 56.04±4.81  55.24±5.36  56.75±5.74 
Leg mass-adjusted strength = (1 RM hamstring curl + 1 RM leg extension) /  
thigh circumference. Values are Means ± SD. 
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